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Abstract
PATHOGENESIS, PATHOLOGY AND CHEMOTHERAPY OF 
EXPERIMENTAL LEGIONELLA PNEUMOPHILA INFECTION
by
Arthur O. Tzianabos 
University of New Hampshire, Decem ber, 1989
Legionella pneumophila is the causative agent of a  severe, often fatal 
pneum onic illness known as  Legionnaires' disease. The m echanism s by which 
L. pneumophila a ttaches to U937 (transformed human macrophage-like cells) 
and to MRC-5 cells (semi-continuous human lung fibroblasts) w ere 
investigated. Experimental param eters for adherence assays w ere established 
prior to blocking studies designed to identify microbial adhesins and/or 
eukaryotic receptors that m ediate bacterial attachm ent to target cells. Results 
from th ese  studies indicated that a  lectin-like com ponent (s) associa ted  with L. 
pneum ophila may be responsible, at least in part, for microbial adherence to 
th ese  eukaryotic host cells. Erythromycin is the drug of choice for the  treatment 
of clinical legionellosis; however, difficulties with this antibiotic have been 
reported resulting in the need to seek alternative therapeutic regim ens. In th ese  
studies, the effect of clinically relevant antibiotics that inhibited bacterial ceil 
wall, protein and DNA synthesis of this pathogen w as evaluated in vitro by 
growth and viability studies a s  well as  morphologically by negative stain,
xv
scanning and thin-section electron microscopy. Of those tested , cefotaxime, an 
antibiotic of limited value in clinical trials, w as most effective. The pathogenicity 
of L. pneumoohila w as a sse s se d  by LD50 and bacterial growth estim ations in 
the chick embryo animal system  in ovo. In addition, histopathological and 
electron microscopic examination of the cellular and sub-cellular pathology 
induced in the organs of em bryos previously infected with 100 times the yolk 
sac  (YS)LD50 of L- pneumophila w as m ade a s  a  prelude to chem otherapeutic 
treatm ent with a  range of clinically putative antimicrobial agents. The promising 
new quinolone derivative, ciprofloxacin, was most effective in these  trials. 
Results from these  studies may be indicative of novel preventative and control 
m easu res for the therapy of human Legionnaires' disease.
x v i
Legionella pneum ophila, serogroup 1 , strain Nottingham N7. Scanning 
electron microscropy (SEM) preparation. Bar=0.5pm.
xv i i
Section I
The Natural History of Legionnaires' Disease
1.1 Preface. L eg ionnaires 'd isease  is a  severe illness of hum ans which 
often occurs in spectacular outbreaks. Although an extensive da ta  base  
concerning all a sp ects  of legionellosis has been established since the outbreak 
in Philadelphia 13 years ago, the m echanism s by which the subsequently 
described causative agent, Legionella pneum ophila, induces d isease  are not 
fully understood. This study exam ines the pathogenesis of this organism at the 
host, cellular and  sub-cellular levels and defines the role of clinically relevant 
antibiotics in th e  d isease  process.
1.2 Historical perspective. The outbreak of a  severe  form of acu te  lobar 
pneum onia during an American Legion Convention held at the Bellevue 
Stratford Hotel in Philadelphia in July 1976 was the precipitating factor which 
led to the isolation and identification of this previously unrecognized human 
pathogen. During this epidemic, 29 of the 182 legionnaires who becam e ill, 
died. An additional 39 individuals who were in or p assed  by the hotel 
developed pneum onia. In all, 34 died from the d isease  or associated  
complications during this outbreak (49). The illness, eventually nam ed 
Legionnaires' d isease , took its nam e from the Philadelphia outbreak. Initially, a  
viral etiology w as suggested  due to the influenza-like symptoms manifested in
1
th e se  people. Indeed, influenza and other bacterial pneum onias are still 
com m on diagnostic considerations by clinicians presented with symptoms of L. 
pneum ophila infection (99).
Failure to immediately isolate the causative agent following the 
Philadelphia epidem ic caused  th e  news media to heighten concerns about the 
p resence  of a  new  microbial killer. These em bellished reports undoubtedly 
expedited the epidemiological and  microbiological investigations following the 
outbreak and contributed to subsequent recognition of this important human 
pathogen. Although investigators at the C enters for D isease Control (CDC) in 
Atlanta announced the cause of the  disease six months after the outbreak, they 
could not identify the mode of transmission but only pointed out that a  common- 
sou rce  epidemic had occurred.
The inability to stain or grow the organism using conventional 
microbiological procedures proved the main problem s in identifying the 
etiological agent of the disease. Dr. Joseph McDade at CDC finally isolated the 
organism  using techniques established for the recovery and identification of 
rickettsiae. The yolk sacs of em bryonated eg g s w ere inoculated with lung 
sam ples from fatal cases  and the bacteria w ere visualized by Gimenez stain 
which contains carbol fucshin rather than safranin. The latter fails to stain 
Legionella species and, as it is the  usual com ponent of the gram  stain, offers 
explanation of the  failure to visualize the agent initially (85). It w as 
subsequently show n that the organism  and the d isease  it c au sed  were not new, 
and  previously unresolved epidem ics were retrospectively attributed to this
2
organism. Among th ese  was an outbreak of a  febrile illness with a  high attack 
rate that occurred in Pontiac, Mi. in 1968 and, due to its non-pneum onic form, 
w as later called "Pontiac Fever" (59). The explanation for the variability of 
sym ptom s of Legionnaires’ d isease  and Pontiac Fever is unknown. The 
spectrum  of d isea se  cau sed  by this and related microorganisms is term ed 
legionellosis.
After attem pted cultivation on 17 commonly used bacteriological media, 
Feeley et al. (43) reported that Mueller-Hinton ag ar supplem ented with 1% 
hemoglobin and 1% IsovitalexR supported sp arse  L. pneumophila growth. 
Feeley-Gorm an agar, which contained added L*cysteine hydrochloride and 
soluble ferric pyrophosphate, was an improvement upon this medium (42). 
Finally, Edelstein (29) introduced a  useful but expensive solid medium which 
contained a-ketoglutarate (BCYEa) that supported substantial bacterial growth
after a  48-72 h incubation period at 37° C. This remains the medium of choice 
for the  cultivation of legionellae in clinical and research laboratories.
Subsequent investigations have dem onstrated that L. pneum ophila is an 
environmental organism  readily found in stream s, lakes and potable w ater and 
w hen delivered in appropriate aerosolized form enters the respiratory tract of 
hum ans and replicates within alveolar m acrophages of the lung (13, 111). Air 
conditioners, humidifiers, evaporative condensers, cooling tow ers and other 
w ater system s capable of generating aerosols are  potential sources of d isease- 
Human-to-human spread  has never been recorded.
Experimental study of the pathogenic a sp ec ts  of the organism has
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utilized a num ber of different laboratory animals, but to date none have fully 
simulated all aspects  of legionellosis. G uinea pigs, rats, mice, rabbits and 
monkeys have been experimentally infected with L. pneum ophila by a num ber 
of different inoculation routes and these  manifest som e, but not all the 
sym ptom s of clinical d isease . Guinea pigs are used  most extensively in such 
studies, but restricted availability, high costs  and legislative p ressu res  have 
forced researchers to seek  alternative system s to study pathogenesis of the 
organism .
1.3 The Organism:
1.3.1 T axonom y and  n o m en c la tu re . The classification and  nom enclature 
of this organism is difficult. Brenner et al. (15, 16) used  DNA homology studies 
a s  the  primary tool to establish that the Legionnaires' d isease  bacterium of the 
Philadelphia outbreak w as a  member of a  new family (Leqionellaceael of the 
gen u s  Legionella and species pneum ophila. Serological diversity within this 
sp ec ies  is well established and  num erous additional species, sub-species and 
serogroups have been described since that time (Table 1.1).
The diversity of the genus has been  noted (15) and attributed to the 
failure of traditional biochemical, immunological and genotypic techniques to 
yield corroborative results. Analysis of fatty acid and isoprenoid quinone 
content have been  useful, but do not accurately differentiate all species and  are 
not appropriate for use outside of a  large research laboratory (15). The 
determination of DNA relatedness has been  and rem ains the main criterion for
4
Table 1.1 Taxonomy and classification of the gen u s L eg io n ella *
Isolated From
S p ec ies  S erogroup  H um ans Environment
L. pneumophila^ 1 Yes Yes
2 Yes Yes
3 Yes Y es
4 Yes Y es
5 Yes Y es
6 Yes Y es
7 Yes Yes
8  Yes No
9 Yes Y es
10 Yes Y es
1 1 Yes No
13 Yes No
14 Yes No
L. micdadei2 Yes Y es
L. bozem anii3 1 Yes Y es
2 Yes No
L. dumoffii3 Yes Y es
L. gormanii3 No Y es
L. longbeachae 1 Yes No
2 Yes No
L. jordanis Yes Y es
L. oakridgensis No Yes
L. wadsworthii Y es No
L. feelii 1 Yes Y es
2 Yes No
L. sainthelensi No Y es
L. an isa No Y es
L. m aceachernii Yes Y es
L. jam estow niensis No Y es
L. rubrilucens No Yes
L. erythra No Yes
(continuation)
L. hackeliae 1 Yes No
2 Y es No
L. spiritensis No Yes
L. parisiensis No Yes
L. cherrii No Yes
L. steigerwaltii No Yes
L. santicrucis No Yes
L. israelensis No Yes
L. birm ingham ensis Yes No
L. cincinnatiensis Y es No
L. moravica No Yes
L. brunensis No Yes
L. quinlivanii No Yes
L. tucsonensis Yes No
‘Adapted from reference 136, Winn, W. C. Jr., Clin. Microbiol. Rev.
1|_. pneum ophila contains three subspecies: L. oneumoohila subspecies 
pneum ophila. L. pneumophila subspecies pascullei and  L. pneum oohila 
subspecies  fraseri.
2Alternate genus name: Tatlockia.
3Alternate genus name: Fluoribacter.
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classification. However, practical identification of Legionella  
species has depended on phenotypic characteristics which include gram
reaction a s  well a s  growth on BCYEa with added L-cysteine and the absence of 
growth on blood agar or BCYEa without added L-cysteine.
The classification of Legionella species has been  som ew hat 
controversial. D isagreem ent continues a s  to the deg ree  of genetic divergence 
that constitutes the establishm ent of a  separate  species a s  well a s  the disparity 
with which researchers have applied criteria to make th ese  distinctions. Brown 
et al. (54) proposed alternate criteria for classification purposes in which two 
new genera, Tatlockia and Fluoribacter. were created. T hese would contain 
organism s otherwise called L. micdadei and the autofluorescing Legionella 
species L. bozemanii. L. dumoffii and L. gormanii. respectively (Table 1.1). 
However, this schem e has not found universal acceptance and m ost workers 
accept the single genus terminology of Legionella within which all species are 
located. It is clear that further work is necessary  to establish uniform guidelines 
for the classification of the legionellae and related species.
1.3.2 Morphological characteristics. Morphological properties of L. 
pneum ophila are  shown in Table 1.2 . Transmission electron microscopy of thin- 
sectioned L. pneum ophila cells has dem onstrated the typical morphological 
characteristics associated  with gram -negative bacteria (105). L. pneumophila 
organism s were shown to be pleomorphic gram -negative rods that m easure 2 
to 20 pm in length and 0.3 to 0.9 pm in width. Artificial media giving poor or
7
Table 1.2 Morphological properties of L. pneum ophila^
Short rods (from autopsied lung 0.6 x 1-2 pm, from agar 0.4 x 2-3 pm) 
Tapered ends
Vacuolated surfaces, convoluted or smooth surfaces 
Long forms fin vivo up to 20 pm in length, in vitro >50 pm)
Internal PBH granules-deform ed in freezed fracture 
Division by nonseptate binary fission 
Flagella and fimbriae (pili) present
Blebs and granules on surface subunits, no evidence of acid polysaccharide 
capsu le
F-1 antigen (serogroup specific) located at bacterial surfaces 
Limiting cell envelope, "unit membrane", 10 nm thick 
Peptidoglycan-like mucopeptide layer present after partial plasmolysis 
P lasm a m em brane, "unit membrane", 10 nm thick 
Rich in ribosomes, 25 nm diam eter
1 Adapted from reference 107, Rodgers, F.G., Legionellosis.
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slow bacterial growth resulted in organism s with an elongated or filamentous 
form with tapered ends. Those rods visualized from autopsied lung were 
consistently shorter (21,105).
The cytoplasm of each organism is enclosed within a  double cell 
envelope of approximately 25 nm thickness with an electron-lucent zone or 
periplasm between the inner and  outer m em branes indicating, like the aquatic 
pseudom onads, an apparent ab sen ce  of peptidoglycan (105). However, 
peptidoglycan and diaminopimelic acid have been  dem onstrated following 
partial plasmolysis and enzymatic digestion of the organism by electron 
microscopy and by other biochemical techniques (46, 105, 107, 108). The 
outer m em branes of organisms contain substantial am ounts of the bacterial 
lipopolysaccharide component, 2-keto-3-deoxyoctonate (46).
Cytoplasmic contents consist of evenly dispersed, electron-dense 
ribosom es, each of 25 nm diam eter, arranged in small groups or polysom es 
and a  fine skein of nuclear material (105, 110, 111). Electron-lucent vacuoles 
have been  dem onstrated as a  regular feature of the cytoplasm of L 
pneum ophila w hether present in human lung cells, guinea pig spleen, 
peritoneal m acrophages or from bacteriological media (107). The reported size
of th ese  vacuoles varied from 30 to 200 nm (13) but larger forms up to 0.5 pm
have been  found (107). These structures have been confirmed a s  poly-(3-
hydroxybutyrate (PBH) granules by their appearance in freeze-fractured 
preparations (107, 108).
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Negative-stain and scanning electron microscopy of L. pneumophila 
revealed bacterial cells with nonparallel sides, tapered e n d s  and smooth 
undulating surfaces. Flagella and fimbriae (pili) have been  demonstrated in 
vitro a s  surface appendages  of L. pneumophila (110). The presence of small 
blebs and evaginations of the outer membrane have been noted on the 
surfaces of organisms by thin-section, scanning and freeze-fracture electron 
microscopy, but an  extracellular mucopolysaccharide layer has not been 
detected. In addition, freeze-fracture electron microscopy of L. pneumophila 
demonstrated four short ridges enclosing the bacterial cytoplasm which 
corresponded to the  double-unit membrane seen  in thin-sectioned material 
(107, 108). Fractured aspects of the peptidoglycan were not evident in the 
intramembranous region of bacilli even after partial plasmolysis.
Poly-p-hydroxybutyrate granules were surrounded by a  non-fracturable
membrane evident a s  a  single ridge in freeze-fracture preparations and 
confirmed reports of electron-lucent vacuoles in thin-sections. In keeping with 
the nature of PBH granules, contents of the granules in L. pneumophila 
underwent plastic deformation a s  an artifact of the fracture process and  were 
evident a s  long, drawn out structures (107,108).
1.3.3 Biochemical properties. L. pneumophila is a  non-spore forming, 
aerobic, non-acid fast organism. All species of the genus demonstrate weak 
catalase and peroxidase activity. L. pneumophila also exp resses  gelatinase,
phospholipase and p-lactamase a s  well as  the ability to hydrolyze starch. Many
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reports describe a  number of exoproteases produced by the organism and 
these  degrade a wide variety of proteins (10, 79). Keen and Hoffman (79) have 
isolated and partially characterized an exoprotease of L. pneumophila that 
exhibited cytotoxic and  hemolytic activity.
L. pneumophila contains an unusually large proportion of branched- 
chain fatty acids located in the cell wall (15) but reports demonstrating the 
p resence of an extracellular acid polysaccharide layer by ruthenium red 
staining have been contradictory (66, 105). The organism has been shown to 
p o sse s s  a  high molecular weight antigen or lipopolysaccharide (LPS), termed 
the F-1 antigen (34, 76) which had endotoxic activity, inhibited serological 
reactions and w as localized on the surface of the bacterium. The LPS of L. 
pneumophila serogroup 1 w as found to be tightly bound to the major outer 
membrane protein (MOMP), reacted specifically with the se ra  of patients with L. 
pneumophila serogroup 1 infection and was distinctly different from that of most 
enteric bacteria (136).
The MOMP of L. pneumophila has a  molecular weight of 24 to 29 
kDa (18, 53, 67, 76, 89) and is expressed on the surface of the bacterium (34). 
Reports have suggested  that the MOMP may be associated with LPS (67) and 
peptidoglycan (52). Gabay and Horwitz (52) showed that this molecule formed 
ion-permeable channels  similar in function to those found in Escherichia coli 
upon exposure to lipid membranes. Butler et al. (18) suggested  that the MOMP 
is part of a  larger, four sub-unit 95 kDa complex.
Investigations have shown that amino acids are the major source of
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energy for growth (55, 80), although the specific amino acid requirements are 
a s  yet undetermined. However, it is generally agreed that arginine, threonine, 
methionine, serine, isoleucine, valine, and cysteine are necessary. In addition, 
several groups have demonstrated that L. pneumophila can be grown in 
chemically defined media composed of amino acids (55, 94). While purines, 
pyrimidines, vitamins and other growth factors are not required, it is known that 
this organism has an unusually high requirement for L-cysteine.
The Krebs cycle is the primary route for carbon assimilation and energy 
production for L. pneumophila (55, 68, 122). These studies have shown that all 
the enzymes of this cycle were present but those of the glyoxylate shunt were 
marginal or absent in cell-free extracts of this bacterium.
Legionellae do not appreciably catabolize carbohydrates. Early reports 
showed negative sugar fermentation results but subsequent studies indicated 
that the Entner-Douderoff and pentose phosphate pathways but not the 
Embden-Meyerof pathway functioned to a  limited degree  in glucose catabolism 
(134). However, the gluconeogenic anabolic enzymes of the Embden-Meyerof 
pathway were responsible for sugar synthesis (55).
L. pneumophila growth is enhanced by trace metals, most notably ferric 
iron, but this may not be an absolute requirement (102,121). Other important 
metals include Cu, Mg, Mn, Co, Ca, Mo, Ni, V, and Zn. In addition, Reeves et al. 
(103) have reported the absence  of phenolate or hydroxamate ferric-binding 
compounds in Legionella species. The function of charcoal and a-ketoglutarate 
in the growth media of this organism has been questioned. Some investigators
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believe that these  compounds neutralize oleic acid produced in the media upon 
autoclave sterilization while others have suggested that they may serve to 
scavenge toxic oxygen radicals released from the yeast extract present in the 
medium upon exposure to fluorescent light (69). However, the precise nature of 
this requirement has  not been elucidated.
The electron transport chain of L. pneumophila is com posed of 
cytochromes c, b, a  and d types but the organization of the respiratory chain 
remains undetermined (68). The concentrations of these  heme-containing 
proteins were much lower in Legionella compared with those of other aerobes 
such as  P seudom onas or Campylobacter. Researchers have concluded that 
the respiratory chain is quite complex in L. pneumophila but is punctuated by at 
least three terminal oxidases (68). The biochemical properties of L. 
pneumophila are summarized in Table 1.3.
1.3.4 Physico-chemical properties. The legionellae have an optimum pH 
range for growth of 6.7 to 6.9 in BCYEa but may grow in other m edia with pH
values a s  low as  6.0 (47, 55). Clinical isolates have an optimal temperature 
range of 35 to 37° C but environmental isolates prefer an optimum of 30° C. 
Isolation of the legionellae from water at 50 to 65° C has been reported (47).
1.3.5 Genetics. Genetic analysis of L. pneumophila has proved difficult. The 
fastidious nature of the organism and lack of conventional genetic transfer 
system s for the legionellae have limited our knowledge in this area . Plasmids ■ 
have been found in L  pneumophila but have not b een  shown to contribute to or 
detract from the virulent properties of the organism. Recent efforts to clone the
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g en es  for Legionella antigens in E. coli have been successful (27, 37, 38). In 
addition, Cianciotto et al. (23) were able to render a  previously virulent strain of 
L. pneumophila non-infectious for cell cultures through the genetic deletion of a  
24 kDa surface protein. Studies such as  these may help further our knowledge 
concerning the pathogenic mechanisms of this organism.
1.3.6 Environmental aspects. The Legionellaceae are ubiquitous in 
natural aquatic habitats and man-made water systems. L. pneumophila has 
been isolated from lakes, streams, rivers, cooling water, hot water and potable 
water system s (48, 86). There is conclusive epidemiological evidence that the 
generation of aerosols from domestic and industrial air-conditioners, 
evaporative condensers, cooling, hot water and other aquatic system s which 
release micron-sized water droplets into the air serve as  potential sources for 
legionellosis (86). An appropriate infectious dose of L  pneumophila may be 
delivered by aerosolized droplets 5 to 15 pm in diameter which can  readily
enter the nasopharynx and penetrate alveolar airspaces of the lung.
L. pneumophila has  been primarily isolated from warm or thermally 
polluted freshwater systems. Although the organism has been found in a  wide 
variety of aquatic niches, it is estimated to comprise a  very small portion of the 
total bacterial population in the aquatic environment.
The association of Legionella with blue-green algae and freshwater 
protozoans including free-living am oebae  A cantham oeba. Tetrahvm ena and 
Cvclidium species  has been demonstrated (3, 113, 124). Such interactions 
have been hypothesized to provide legionellae with an abundance of nutritional
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support and a  host in which microbial numbers can be amplified. Evidence 
presented by Berendt (11) suggested that the survival of L. pneumophila in an 
aerosolized form w as enhanced by its association with various species  of the 
blue-green algae, Fischerella. and that dissemination away from the source of a 
generated  aerosol may be aided by particular algal components. Results from 
other studies (127) indicated that legionellae may be carried in aerosolized 
form in cooling tower plumes 20 to 50 kilometers downwind and illustrated the 
potential danger posed by this pathogen.
The eradication of legionellae from water system s is rarely possible and 
studies should center on determining acceptable microbial densities for the 
organism. Effective biocidal treatments are being investigated for u se  as  control 
and preventative m easures. The most effective potable water treatments have 
been shown to be hyperchlorination, especially of hot water supplies and 
heating to above 50° C. Acceptable treatments for non-potable water included 
chlorination, use of quaternary ammonium compounds and halamines (118).
1.4 The Disease
1.4.1 Epidemiology. Legionellosis can exist in two forms: the severe  
pneumonic type with associated high fever known a s  Legionnaires' d isease  
and the  non-pneumonic form known as  Pontiac Fever. Table 1.4 lists the 
symptoms for these  conditions. The d isease  can occur a s  epidemics, sporadic 
cases , or nosocomial infections. Epidemic legionellosis has been documented 
in many countries including the United States, Great Britain, Spain, The 
Netherlands, Germany, Sweden, France, C anada  and Italy and shows an
16
Table 1.4 Comparison of symptoms of patients with Legionnaires' 




Sputum production Yes No
D yspnea Yes No
Hemoptysis Yes No
Myalgias Yes Yes
Upper respiratory symptoms Yes No
H eadache Yes Yes
Confusion Yes Yes
N ausea or vomiting Yes Yes
Diarrhea Yes Yes
Abdominal pain Yes No
Fever Yes Yes
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increase in incidence during the summ er months of July, August and 
Septem ber (Figure 1.1). L. pneumophila serogroup 1 is responsible for 85% of 
reported c a ses  of legionellosis while L. micdadei causes  approximately 6%
(136). A number of species of Leoionella have been isolated from human and 
environmental sources. The most recognized form of legionellosis, 
Legionnaires' d isease, has an incubation period of 2 to 10 days with an attack 
rate of 1 to 5% and a  case-fatality ratio of 0 to 40% (84,139). It has  been 
estimated to be responsible for 1 to 29% of community acquired pneumonia. 
A ssessm ents  of this nature have been difficult due to the environmental nature 
of Legionella and the difficulty in establishing an etiology for many undiagnosed 
pneumonias. Table 1.5 illustrates the clinical presentation of legionellosis.
The d isease  exhibits a  predilection for immunocompromised individuals. 
The risk of development of Legionnaires' d isease increases in the elderly and 
in those  who excessively smoke and/or drink alcoholic beverages. In addition, 
underlying illnesses such as  diabetes mellitus, congestive heart failure, 
malignancy, obstructive pulmonary d isease  or use of immunosuppressive 
medication may increase susceptibility to this opportunistic pathogen.
It has been demonstrated that airborne transmission of aerosolized 
organisms is the mechanism by which the organism and hence the  disease 
disseminates, but identification of pin-point sources of the infection in epidemic 
legionellosis are often difficult. Investigation of the Philadelphia outbreak did 
not conclusively demonstrate the source of the epidemic, but studies showed 












1978 1979 1980 1981
Figure 1,1 Average incidence of Legionnaires' d isease  ca ses  reported to the 
CDC from 1978 to 1981. Note higher incidence during the summer months of 
each year. Reprinted with permission from Legionellosis, S. M. Katz (ed.), 
copyright CRC Press, Inc. Boca Raton, FI.
Table 1.5 Clinical presentation of leg ionellosis
Two forms: Legionnaires' d isease (LD) and Pontiac Fever (PF) 













Kidneys, G.l. tract, CNS 
Variable 0-40%
Pontiac out break 
95%





may have been a  significant risk factor. However, the development of illness in 
people who never entered the hotel but were in c lose  proximity was suggestive 
of airborne transmission. That evaporative condensers  and air handling 
equipment have been identified a s  the source of o ther outbreaks further 
substantiated this hypothesis (84, 86).
The first reported case  of Pontiac Fever w as  recognized retrospectively 
following the  events of the Philadelphia epidemic. The Pontiac Fever outbreak 
occurred in July 1968 in a  health department in Pontiac, Mi. and this episode 
provided significant evidence of airborne transmission of organisms from a  
evaporative condenser (59). Between the time that the first illness was reported 
until two days  later, 89 of the facility's 100 employees and 15 visitors becam e 
sick. All c a s e s  had no common exposures outside the  building and people 
working in all a reas  of the building were exposed. However, attack rates were 
higher in persons exposed during the morning than in people newly exposed in 
the afternoon suggesting increased risk after the air-conditioning system w as 
first turned on each day. Subsequent investigation revealed that the central air- 
conditioning unit for the building w as contaminated by an adjacent evaporative 
condenser.
Similar instances have been documented w here burst exposure of 
individuals to aerosols or air handling equipment contaminated with L. 
pneumophila have led to illness. Most notably, a  study of recurrent 
Legionnaires' d isease in a  hotel in Spain revealed that members of married 
couples who were the first to shower in the morning had contracted
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legionellosis in fi/e of six c a ses  (5). T hese  data may indicate that inoculum size 
of L. pneumophila is a  contributing factor to the initiation of disease.
Sporadic cases  of legionellosis outnumber epidemic c a s e s  by a  two to 
one ratio. This ratio may even be higher given the probability that only 0.8 to 
2% of these  c a se s  are reported each year. According to the surveillance 
system of the CDC, from the period of 1978 to 1981, sporadic c a ses  had been 
reported in every one of the  states of the USA, occurred primarily in the summer 
months and had an incidence ranging from less than 0.25 to more than 1.0 
c a s e s  per 100,000 people (Figure 1.2). Sixty-six percent of c a s e s  were in 
persons greater than 50 years old (84).
Tobin et al. (125) were the first to suggest that hospital water systems 
other than cooling units could act a s  reservoirs for L. oneumoohila.
Subsequent investigations have substantiated that potable water is a  potential 
source of nosocomial or hospital-acquired legionellosis (1). Environmental 
sampling in several hospitals has led to the isolation of L. oneumoohila and 
other species from a variety of sources including shower heads, tap water, 
medical drills and respiratory therapy equipment (1, 4 ,17). Reports vary as  to 
the incidence of hospital-acquired Legionella infections but th e se  range from 0 
to a s  high a s  30%. In general, investigators actively searching for Legionella as 
a  cause  of pneumonia tend to find it to a  greater frequency.
The incidence of nosocomial Legionnaires' d isease  can be attributed to 
the ubiquity of the organism in hospitals and the presence of a  susceptible 













Figure 1.2 Reported sporadic c a se s  of legionellosis to the CDC from 1978 to 
1981 indicating average incidence per 100,000 individuals per state. Reprinted 
with permission from Legionellosis, S. M. Katz (ed.), copyright CRC Press, Inc. 
Boca Raton, FI.
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immunity were the greatest risk factors for acquisition of d isease  by patients. 
Interestingly, the widespread presence of legionellae in water sources of 
hospitals d o es  not correlate well with the incidence of disease. Explanations for 
this phenomenon include colonization of water lines with non-virulent 
legionellae, presence of sub-infective d oses  of organisms and variations in the 
susceptibility of patients. Further studies are needed to determine the pre­
existing conditions within a  hospital which are most likely responsible for the 
incidence of nosocomial Legionnaires' disease.
The most perplexing issues concerning the epidemiology of legionellosis 
is the manifestation of two separate illnesses, Legionnaires' d isea se  and 
Pontiac Fever, from infection with the sam e  organism. No differences can be 
attributed to the bacterium or to conditions surrounding outbreaks to explain 
discrepancies in symptoms, attack rate or incubation period. It is possible that 
either the infectious dose  for each d isease  varies or alternatively that patient- 
related differences may be responsible. To date no evidence h as  accumulated 
to support either of these  hypotheses. Further work is needed to determine 
whether this phenomenon is related to other pathogenic features exhibited by L, 
pneum ophila .
1.4.2 Clinical features. Legionellosis is two to three times more common in 
men than in women and infections in children are rare. The d isea se  presents 
a s  an atypical lobar pneumonia and has  an incubation period of 2 to 10 days. 
The infection begins with acute fever, rigors, headache and myalgia. Upper 
respiratory tract symptoms are often absen t and a  non-productive dry cough
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may appear three to four days later. On occasions when sputum is produced it 
is often non-purulent. Dyspnea and respiratory difficulties are  common. 
Extrapulmonary symptoms such a s  gastroenteritis, fatigue and confusion are 
often reported and commonly lead to misdiagnoses by clinicians (see Tables
1.4 and 1.5). Legionellae are difficult to isolate from respiratory secretions but 
may be readily demonstrated in direct lung biopsy by immunofluorescence.
1.4.3 Pathology. X-ray radiographs of patients with Legionnaires' d isease  
have been variable and do not uniquely identify Legionella pneumonia. An 
average  of three days occurs between the onset of symptoms and the 
appearance  of radiographic pathology (40, 81). Deterioration of lung has been 
seen  in two-thirds of c a ses  and the most common features noted are the 
appearance  of infiltrates and pleural effusions. Usually one lobe is affected but 
bilateral involvement has occurred in approximately one-quarter of reported 
c a s e s  (81). The resolution of radiographic problems has often taken longer 
than that of clinical recovery and may require an extended period of 
convalescence. Post-mortem lung samples have demonstrated the 
development of fibrino-purulent d isease in one or both lungs with focal or lobar 
consolidation, edem a, congestion and grey hepatization. In most cases , a 
fibrinous exudate is present in the pleural cavity. Macroscopic lesions are not 
always present but can include hemorrhagic a reas  and focal ab sc e ss  formation 
(14).
Microscopic examination has revealed a  severe inflammatory response 
within the distal a irspaces of the lung. Terminal bronchioles and alveoli are
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filled with proteinaceous material, fibrinous exudate and contain numerous 
m acrophages and polymorphonuclear leukocytes (PMNLs) presenting in 
varying proportions. Proximal bronchi and bronchioles usually remain 
uninvolved throughout the d isease process. Alveolar dam age with hyaline 
m em branes and desquamation of lining cells has been noted in lung biopsies 
(90, 136).
Shortly after the initial outbreak in 1976, Rodgers et al. (111) first 
demonstrated the presence of L. pneumophila within lung cells by electron 
microscopy and described ultrastructural degenerative changes  associated with 
further dissemination of the organism into alveolar extracellular spaces. These 
findings were subsequently confirmed by other ultrastructural reports which 
described the intracellular nature of the organism (105, 106, 107).
Several investigators have demonstrated that patients with severe illness 
have developed extrathoracic pathology that involved the kidneys, heart, liver, 
spleen and brain. Instances of pyelonephritis, hepatic a b scesses ,  cerebral 
myoglial reactions, pericarditis and endocarditis have been reported (4, 136). 
Degenerative changes  have been found in these  organs, but macroscopic 
lesions are uncommon.
Unusual complications such as  dual infection with multiple species (26) 
or subtypes (78) of Legionella or other opportunistic pathogens have been 
reported. In addition, serologic confirmation of sub-clinical infection and diverse 
clinical presentation of d isease  following repeated exposure to the sam e source 
of L. pneumophila has been described (58, 136).
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1.4.4 Pathogenesis. L. pneumophila is a  facultative intracellular pathogen 
which replicates within alveolar m acrophages of the lung. During the course of 
infection, the bacteria are actively phagocytosed by host cells and enter 
phagosom es associated  with ribosomes and mitochondria. Phagocytosis of L 
pneumophila by m acrophages is independent of, but enhanced  by, the 
p resence  of opsonizing antibody and complement. However, phagocytosis by 
PMNLs requires the  presence of antibody, is not bactericidal and d o es  not 
support the growth of L. pneumophila. Direct penetration of bacteria into 
eukaryotic cells h as  been suggested  but uptake of L. pneumophila by guinea 
pig m acrophages h a s  been shown to occur by a conventional phagocytic 
process (36).
Studies have shown that macrophages exhibited an oxidative burst upon 
internalization of virulent L. pneumoohila but subsequent events such a s  
phagolysosomal fusion and acidification of the phagosom e were inhibited (71, 
73). Rapid intracellular multiplication of L. pneumoohila w as followed by 
cellular lysis with re lease  of organisms and continued sp read  to adjacent host 
cells. Further sp read  of the organism via the bloodstream has been described 
and m ay explain the  extrapulmonary pathology observed during advanced 
stages of the d isease  process (31, 105,136).
Although no single microbial feature h as  been shown to confer virulence 
on L. pneumophila , a  number of bacterial products have been implicated as 
potential factors which contribute to its pathogenicity. R elease of toxins which 
neutralize the bactericidal pathways of phagocytes (50) and  induce necrotizing
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inflammatory and cytolytic responses in human tissues (6, 10) may be the most 
important pathogenic aspects of the legionellae.
1.4.5 Diagnosis. Difficulties involved in the diagnosis of L. pneumophila  
infections are due primarily to the similarity between symptoms of Legionella 
infections with those of other bacterial and viral pneumonias and the non- 
pathognomic radiographic appearance of the disease. In addition, failure to 
stain the organism in clinical sam ples further complicates positive identification 
of legionellae as  the causative agent. These problems make it necessary to 
rely on culture, serology, and detection of bacterial nucleic acid or antigen as 
the main methods for the diagnosis of Legionnaires' d isease. Table 1.6 
illustrates clinical and laboratory diagnostic indicators of legionellosis.
The mainstay of laboratory diagnosis remains culture on selective 
bacteriological media {31, 137). Growth on BCYEa with supplemented L-
cysteine in the absence  of growth on a  blood agar media is indicative of JL 
pneumophila. Recovery of clinical specimens by culture will identify 50 to 80% 
of positive samples and  this has been reported to have a  specificity of 100%
(137). Colonial morphology is distinct and requires two to five days for positive 
identification. Once isolated, confirmation of these  tests should be m ade by a 
gram stain in which carbol fucshin is substituted for safranin as  the counter-stain 
along with immunofluorescence. Figure 1.3 illustrates the rationale for 
determining the laboratory detection of L. pneumophila.
The development of a  variety of serological tests  including indirect 
immunofluorescence assay s  (IFA) has  been useful in the identification of
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Identification S c h e m e  for L. pn eum ophila
Growth on BCYEa of gram-negatiYe bacillus
N o __________________ 1_____________________ Yes
I I
Not L. pneum ophila Potential L. pneumophila
I----------------------------  1
Growth on B C Y Ea without L-cysteine 
at 37 ° C in 3 days
Y e s _____________ J_______________ No
I I
Probably not L. pneumophila Possible L. pneumophila
I
Growth on  blood containing ag a r  
I
Not L. pneumophila
Immunofluorescence or Agglutination 
Positive----------------1---------------- Negative
Presumptive L. pneumophila Probable L. pneum ophila
B ioc hem icaIA na lysis for co nfirmation
Figure 1.3. Flow schem e for the identification of L. pneumophila.
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Legionella antibody for diagnostic purposes. Although, IFA has a  sensitivity of 
approximately 75% and a  specificity of almost 100%, problems have arisen in 
its use for diagnosis of sporadic ca ses  of Legionnaires' d isease. This is due to 
the incidence of cross-reactivity reported with the use of L. pneumoohila 
antibody and the inherent difficulty involved in the subjective interpretation of 
the assay. Detection of seroconversion to a  four-fold titer by serological 
methods is useful, but yields retrospective results and should be interpreted 
with caution (4, 64, 137).
Direct observation of L. pneumophila antigen in clinical specimens by 
IFA has provided relatively rapid diagnoses but with low sensitivity. Problems 
due  to reagent cross-reactivity with other bacteria and the environmental 
presence of the legionellae have lead to false-positive results (4, 64). 
Commercial nucleic acid probes are now available and exhibit better sensitivity 
than IFA, and although they are gaining widespread acceptance, further 
examination is needed before they replace IFA completely.
Radioimmunoassay, latex agglutination, microagglutination, counter immuno- 
electrophoresis, hemagglutination and enzyme immunoassay techniques have 
been used or are currently being investigated for application as  rapid, sensitive 
and  specific diagnostic tools (64, 114).
1.4.6 Immunity. The immune response to Legionnaires' d isease  is not well 
understood. However, epidemiological evidence has suggested  that 
susceptibility and resistance to Legionella infection are  directly related to risk 
factors which usually immunocompromise the host. Advanced age, underlying
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disease, excessive cigarette smoking and immunosuppressive therapy have 
been shown to influence attack and fatality rates of Legionnaires' disease. 
Experimental studies have demonstrated that the cellular arm of the immune 
system may have a significant role in resistance to infection with L. 
pneumophila. Freidman et al. (51) demonstrated that lymphokine activated 
m acrophages did not support the growth of ingested legionellae while Horwitz 
et al. (72) show ed that non-specific activation of these  cells also inhibited 
intracellular replication of Legionella. That untreated alveolar macrophages of 
mice did not support intracellular growth of this organism (140) further 
suggested that aspects  of the bacteria-macrophage interaction have a central 
function in the immune response to legionellosis.
The role of humoral immunity has  not been well-defined. Theoretically, 
the introduction of anti-L. pneumophila antibodies would facilitate opsonization 
of bacteria with detrimental results to the host. However, animal studies have 
demonstrated that passive transfer of antibody against L. pneumophila is 
effective against subsequent challenge with whole organisms (104, 136).
It has b een  difficult to establish whether individuals who have contracted 
legionellosis a re  susceptible to re-infection. Researchers have shown that 
immunization of guinea pigs with killed antigen is protective in so m e  cases, but 
not in others (7, 33). Winn and Davis (136) were able to protect guinea pigs for 
one month after infection by aerosol or intratracheal route with a  sub-lethal 
inoculum of L. pneumophila.
Human defenses  against legionellosis most likely involve synergistic 
action of the cellular and humoral immune system. Studies that have elucidated a
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defense system in animals have demonstrated limited bacterial Killing or 
bacteriostasis of L. pneumophila. Further work is needed to fully delineate the 
m echanisms of human resistance to Legionnaires’ d isease.
1.4.7 Antimicrobial Therapy. Erythromycin is the current clinical drug of 
choice for legionellosis. Studies have shown that the clinical reaction to this 
antibiotic may range from an immediate response to no therapeutic results at all. 
Relapse of infection and development of severe phlebitis with intravenous use of 
erythromycin have been reported (62). Rifampicin is generally considered the 
most effective drug in vitro and has been used effectively in combined clinical 
therapy with erythromycin, but can not be used alone due to the high frequency 
with which bacterial resistance is induced. Consequently, alternative antimicrobial 
therapeutic regimens are  being sought for the treatment of clinical legionellosis.
L. pneumophila is sensitive to a wide variety of antibiotics in vitro (30, 60, 
123). However, these  sensitivity levels are not always reflected in clinical trials. 
Antimicrobial agents with an effective minimum inhibitory concentration (MIC) such 
a s  the aminoglycosides, cephalosporins and penicillins are  reported a s  ineffective 
in the treatment of human Legionnaires' d isease  (82) while others such a s  
erythromycin, rifampicin and the tetracyclines have an effective role in therapy (2). 
Discrepancy between experimental and clinical trials may b e  explained by the 
inability of various antibiotics to penetrate host cell m em branes and reach 
intracellular bacteria. Indeed, it h as  been reported that ciprofloxacin, erythromycin 
and rifampicin (65, 130) inhibit intracellular growth of L. oneumoohila in cell 
cultures, while the p-lactam antibiotics such a s  ampicillin, cefoxitin and cefotaxime 
do not (142).
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Of the new antibiotics examined, the quinolones have shown great promise 
in vitro and in animal studies (44, 45, 60, 128, 129). Ciprofloxacin, the best 
studied compound of this group, is a  broad spectrum antibiotic which offers 
exceptional oral bioavailability and achieves high tissue concentrations. It is well- 
tolerated by patients and has been used successfully in the clinical treatment of 
various urinary and respiratory tract infections. Results from animal studies 
indicated that the efficacy of ciprofloxacin is equal to or greater than that of 
erythromycin and rifampicin in treatment of experimental Legionella infections (44, 
45 ,128 , 129). Further studies are in progress to develop practical in vivo 
screening methods for the evaluation of new antimicrobial agen ts  for treatment of 
clinical Legionnaires' d isease.
Despite the massive accumulation of d a ta  concerning the nature of L. 
pneum ophila since its initial isolation and identification following the epidemic in 
Philadelphia, Legionnaires' d isease  remains a  major cause  of pneumonia in 
humans. Enhanced aw areness of this syndrome and aggressive therapeutic 
regimens have helped in the maintenance and treatment of legionellosis, but 
further studies are needed  to establish prophylactic or preventative m easures  
especially for "at risk groups". Elucidation of the pathogenic m echanisms of the 
organism and the role chemotherapeutic agents  play in the treatment of d isease 
as  well a s  the investigation of the mechanisms of attachment and penetration used 
by I., pneumophila to initiate the d isease process may lead to new developments 
in the control of this important human disease.
3 4
Section  II
2. Hypothesis and Specific aims.
L. pneumophila is the causative agent of a  fatal form of pneumonia 
known as  Legionnaires' disease. The organism is a  facultative intracellular 
pathogen which a ttaches to, penetrates and replicates within alveolar 
m acrophages of the lung. Continued growth and sp read  of L. pneumophila 
leads to the presentation of well-defined clinical features as  well a s  to extensive 
pulmonary and extrapulmonary pathology. The mechanisms by which L 
pneumophila recognizes and attaches to host cells are crucial to the initiation of 
d isease  in a  susceptible host. The process of binding was investigated using 
human cells in culture in order to elucidate these earliest s tages  of microbial 
infection. It is postulated that determination of th ese  adherence events will lead 
to better understanding of the nature of this infectious disease and to the 
development of more effective control measures. Of the present therapeutic 
regimens, erythromycin is the preferred drug for treatment of Legionnaires' 
d isease. However, patients in the advanced s tages  of severe illness often 
respond poorly to such antimicrobial treatment. The in vitro activity of 
established antibiotics along with novel, potentially useful drugs were evaluated 
against the organism per se  to define the kinetics and  mode of action of these  
antimicrobial agents. Furthermore, th e  in vivo pathogenesis  and pathology 
induced in experimental L. pneumophila infection in the chick embryo were
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examined and the ability of clinically proven or potentially useful antibiotics to 
control or ameliorate the disease process was investigated in this animal 
system. From the results of these combined studies it is anticipated that novel 
preventative or control m easures may be forthcoming for the treatment of 
Legionnaires' d isease.
Specific aims of this project w ere:
1) to establish the experimental parameters leading to the characterization of 
Legionella pneumophila adherence factors by using the human cell lines U937 
(macrophage-like) and MRC-5 (lung fibroblast) to partially define these 
adhesins;
2) to elucidate the in vitro activity of selected antibiotics on the growth and 
morphology of Legionella pneumophila:
3) to delineate the cellular and sub-cellular pathology induced in the chick 
embryo following experimental infection with Legionella pneumophila and to 
define the pathogenesis of infection in this system;




Partial Characterization of Legionella pneumophila 
Adherence to Host Cells
3.1 Abstract
The m echanisms by which the facultative intracellular pathogen, 
Legionella pneumophila, attached to macrophage-like (U937) and human 
embryo lung (MRC-5) cells in vitro was examined. Bacteria and host cell 
surfaces were modified or treated with degradative enzymes, detergents, 
fixatives, lectins, oxidizing chemicals, and sugars prior to adherence a s say s  in 
order to elucidate putative bacterial adhesins and eukaryotic receptors 
responsible for mediating specific bacterial binding to these  cell lines. Bacterial 
attachment to host cells was determined by viable count and indirect 
immunofluorescence assay methods. Results from these  studies suggested 
that one or more lectin-like structures on the surface of L. pneumophila 
organisms may potentiate the specific recognition of eukaryotic host cells.
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3.2 Introduction
The specific recognition of host cells by pathogenic bacteria forms a 
necessary  prelude to the initial stages of the disease state (8 ). Duguid (28) first 
coined the term "adhesin" in 1959 to describe the adhesive structures on 
bacteria which facilitate their ability to attach to susceptible eukaryotic cells. This 
work remained largely unnoticed until Gibbons (56) reported on the adherence 
of bacteria to specific a reas  of the oral cavity. Since that time, numerous and 
extensive investigations (9, 25, 39, 41, 92, 93, 95, 96, 97, 98, 100, 117, 119,
120 , 126, 131, 132) concerning the interaction of pathogenic organisms such a s  
Escherichia coli. Neisseria gonorrhoeae. Vibrio cholerae and Streptococcus 
pyogenes  with host cells have increased our understanding of how bacteria 
initiate disease. These  reports described experiments in which the in situ 
blocking, inhibition or enzyme degradation of putative bacterial adhesm s and 
eukaryotic receptors were designed to identify these structures and characterize 
the nature of microbial adherence to host cell surfaces. Further studies 
demonstrating the inhibition of binding by these isolated bacterial 
com ponents/adhesins or by adhesin/receptor specific antibody provided 
additional evidence that these  molecules were responsible for bacterial 
attachment. Although a  number of these structures have been implicated by 
these  methods, pili are  the best studied (98, 119) and have been shown for a 
number of bacterial species to act sequentially or concomitantly with other 
attachment factors (39, 131) during the binding process.
The elucidation of adhesins and their receptors has led to the
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development of novel strategies for the prevention and control of infectious 
d iseases. Prophylactic or post-infection treatment with anti-adherence vaccines 
and purified adhesin/receptor or adhesin/receptor analogues used in a  
competitive fashion have yielded encouraging clinical results (8 ). In addition, 
studies have indicated that sublethal doses of antibiotics may alter the ability of 
some bacteria to adhere to host cell surfaces (22).
L. pneumophila is a facultative intracellular pathogen which replicates 
within alveolar macrophages in clinical d isease  but has been shown to multiply 
within a wide variety of eukaryotic cells in vitro (36, 74, 75, 91, 138). The 
preliminary steps involved in the attachment of this organism to potential host 
cells prior to invasion have not been elucidated. However, L  pneumophila has 
been shown to p o sse s s  pili, fimbriae and flagella (108, 110) on their surface 
and these , as  pointed out by Rodgers (106) and Figure 3.1, may potentiate 
binding by bridging the gap between the negatively charged surfaces of the 
invading pathogen and host target cells.
Oldham and Rodgers (91) studied the interaction of L. pneumophila with 
MRC-5 cells, a  human embryonic lung cell line, both quantitatively (viable 
counts following eukaryotic cell lysis) as well a s  qualitatively (by electron 
microscopy). Attachment of the legionellae to cells was followed by a  
thickening of eukaryotic cell membranes and the proliferation of microvilli which 
led to bacterial endocytosis by a  process which they termed "bacteriopexis". 
More recently, Cianciotto et al. (23, 37) used U937 cells, a  macrophage-like, 
human histiocytic lymphoma cell line, as  a  cellular model of infection and
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suggested that a 24-kDa surface protein of L. pneumophila potentiated 
infectivity and subsequent intracellular replication. In addition, because  similar 
results with explanted human alveolar m acrophages were obtained, these 
investigators have demonstrated the relevance of this transformed cell line in 
the study of L. pneumophila pathogenesis in vitro.
Patients with systemic Legionnaires' d isease  often respond poorly to 
antibiotic therapy. Vaccines prepared to stimulate antibody production against 
whole L. pneumophila organisms lead to avid opsonophagocytosis by the 
"preferred" host cells (macrophages) and may prove counterproductive to 
therapy. The objective of this study was to conduct preliminary studies on the 
attachment of L  pneumophila to U937 and MRC-5 cells a s  a  prerequisite to 
infection at the cellular level. Specific goals included the development and 
establishment of the experimental parameters for adherence assays  as  well as 
the partial characterization of bacterial "adhesins" and eukaryotic receptors 
involved in the "recognition" process. Fixatives, lectins, detergents, oxidizing 
chemicals, degradative enzymes and sugars were used to modify either 
bacterial or eukaryotic cell surfaces. Following these treatments, L, 
pneumophila was added  to the test cells and adherence assay  experiments 
performed. Viable counts of organisms (following eukaryotic cell lysis) and 
immunofluorescence assays  (IFA) (for direct counts of labelled bacteria) were 
done and the number of bound organisms following adherence was 
determined. Percent inhibition of binding w as ascertained by direct comparison 
of results from treated and untreated control trials.
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Due to the complexity of the bacterial and host-cell membranes, data  
derived from studies of this nature are often hard to interpret and the 
experimental procedures often lead to contradictory results making definitive 
adherence criteria difficult to elucidate (8 , 70, 120). For th ese  reasons, 
researchers have b a sed  their conclusions upon well-controlled, stringently 
analyzed experiments. It has been generally accepted that only those 
experimental treatments that inhibited bacterial adherence at a  level equal to or 
greater than 50% of untreated controls were significant. In the present study, 
similar inhibition levels were used to measure the experimental significance of 
treatments for the binding of L. pneum ophila to U937 or MRC-5 cells. In 
addition, because  quantitative measurem ents of bacteria binding are often 
difficult to a s se s s  accurately, two different types of assay  methods were used, 
and the results cross-referenced, to evaulate bacterial binding to host cells.
The identification of the factors that lead to bacterial adherence will help 
characterize the initial s tages of bacterial invasion of host cells and increase our 
understanding of the pathogenic properties of L. pneumophila. The results from 
these studies may suggest potential clinical regimens for blocking infection at 
the cellular level or the development of split vaccines leading to novel 
approaches in the prevention and control of Legionnaires' d isease .
3.3 Materials and Methods
Reagent formulations and preparations along with detailed procedures 
are given in Appendices 1 and 4.
Bacterial strain and cultivation. L. pneumophila serogroup 1, strain
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Nottingham N7, was isolated from the sputum sample of a  fatal case  of 
Legionnaires' d isease, subsequently passag ed  on bacteriological media, and 
maintained fully virulent in a  frozen state in serum sorbitol at -70° C. Cultures
were grown on buffered charcoal yeast extract agar supplemented with a- 
ketoglutarate (BCYEa) (29) a s  previously described {128, 129) at 37°C for 48 h.
To ensure the use of a  consistent population of organisms in all experiments, L 
pneumophila were harvested from plates, inoculated into buffered yeast extract 
broth supplemented with a*ketoglutarate (BYEa broth) (112) to give a  initial
concentration of approximately 1 os organisms/ml and incubated in a  shaking 
water bath for 24 h at 37oC until the culture had reached approximately 2-3 x 
108 colony forming units (cfu)/ml as  determined by subsequent viable counts. 
Bacteria were harvested by centrifugation at 3000 x g in a  Beckman Microfuge 
12 (Beckman Instruments, Palo Alto, Ca.). This procedure did not alter either 
the ability of organisms to adhere to eukaryotic cells or influence the LD50 for 
the fertile hen 's  egg (see Section 5). Organisms were w ashed  in Hank’s 
Balanced Salt Solution (HBSS) (Irvine Scientific, Santa Ana, Ca.) and diluted 
1 :10 in HBSS prior to adherence assays. The ratio of bacteria to cells w as 
approximately 100:1 for both cell lines used in these trials. The rationale for the 
selection of this multiplicity of infection (MOI) as  the inoculum for both cell lines 
w as based on da ta  derived from a) bacterial adherence experiments (see 
Adherence to U937 and MRC-5 cells, p. 44) and  b) adherence  studies on other 
microorganisms in which an inocula of 100 MOI was used.
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Eukaryo tic  cells  a n d  grow th co n d it io n s .  U937 cells. U937 cells, 
derived from a  histiocytic lymphoma cell-line, were obtained from the ATCC 
(Rockville, Md.) and maintained as  replicative, non-adherent monocyte-like 
cells in Minimal Essential Medium with Earle's salts (MEM) (Irvine Scientific, 
Santa  Ana, Ca.) supplemented with 10% bovine calf serum (Hyclone 
Laboratories, Inc., Logan, Utah) and 3mM L-glutamine (Sigma Chemicals, St. 
Louis, Mo.). The cells were grown in T-75 cm 2 flasks (Costar, Cambridge, Ma.) 
and harvested for use in adherence trials at points when the culture reached 
late exponential phase of growth (1-2 x 106 cells/ml). At this stage, the cells 
were differentiated into a non-replicative, adherent macrophage-like cell line 
with 12-O-tetra decanoylphorbol-13-acetate (TPA) (Sigma Chemicals, St. Louis, 
Mo.), which w as added at a  final concentration of 10-0 M for 48 h. Cells were 
removed from flasks with 0.2% EDTA, w ashed with media, and distributed into 
24-well plastic plates (Costar, Cambridge, Ma.) at a cell density of 4-8 x 105 
cells/well for use  in viable count adherence assay s  or into similar 6 -well plates 
containing g lass  coverslips at a  cell density of 5-8 x 105 cells/well for u se  in IFA 
counts.
MRC-5 cells . MRC-5 cells, a semi-continuous, adherent line of human 
embryonic lung fibroblasts, were obtained from Flow Laboraties (McLean, Va.) 
and maintained in MEM supplemented with 10% bovine calf serum and 3 mM L- 
glutamine. Cells were grown to a  confluent s tate  in 24-well or 6 -well plates (on 
glass coverslips) and used directly for viable count or IFA L. pneumophila 
adherence assays . Confluent cell monolayers reached a  density of
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approximately 1-2 x 105 cells/well in 24 well plates and  approximately 2-3 x 105 
cells/coverslip in 6 well plates.
Adherence to U937 and MRC-5 cells. To determine the maximum 
bacterial binding capacity to both cell types in these assays , L. pneumophila
w as grown in BYEa broth for 24 h as described. Cultures were pooled,
centrifuged, serially diluted ten-fold and each  dilution added to 6 and  24-well 
plates containing either U937 or MRC-5 cells for 1 h. The number of organisms 
bound to each cell type was assayed by viable count and  IFA methods to 
determine the specificity of bacterial attachment to th ese  cells.
Inhibition of adherence. Bacterial treatm ents. The role of L, 
pneumophila surface proteins and sugar moieties in the  adherence process 
w as examined. L. pneumophila was treated with degradative enzymes, 
detergents, fixative and oxidizing chemicals and adherence determined by the 
viable count and IFA methods described below {p. 45-47). The type, treatment 
time, concentrations and mode of action of the agents used  to modify the 
surface of the bacteria are shown in Table 3.1. All agents, with the exception of 
glutaraldehyde (Electron Microscopy Sciences, Ft. Washington, Pa.), were 
obtained from Sigma Chemicals (St. Louis, Mo.) and prepared at the 
concentration specified in HBSS prior to testing. Bacteria were treated  with the 
test agent for the time indicated, washed three times in HBSS and used  in the 
adherence a s say s  (p. 45)
Eukaryotic treatments. The role of eukaryotic surface protein, 
glycoprotein, lipid, glycolipid or sugar w as examined a s  possible adhesins in
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the binding process. The type, treatment time, concentrations, and mode of 
action of the degradative enzymes, detergents, fixatives, oxidizing chemicals 
and lectins used to modify the surfaces of U-937 and MRC-5 cells are shown in 
Table 3.2. All agents were obtained from Sigma Chemicals (St. Louis, Mo.) with 
the exception of the glutaraldehyde and formaldehyde (Electron Microscopy 
Sciences, Ft. Washington, Pa.) and prepared at the specified concentration in 
HBSS prior to testing. Cells were treated with agents for the time indicated and 
w ashed three times with HBSS prior to adherence assays.
S u g ars . A number of sugars were examined as  possible inhibitors of the 
attachment process by conducting adherence assay s  in the presence of these 
carbohydrates. Monosaccharides (Sigma Chemicals, St. Louis, Mo.) used  in 
these  studies are  shown in Table 3.3. Sugars were prepared at the specified 
concentrations in HBSS, adjusted to pH 7.2 and added to cells 10 minutes prior 
to the addition of L. pneumophila for adherence experiments.
Adherence assays. U937 and MRC-5 cells were w ashed three times 
with HBSS prior to adherence experiments. Following either treatment of 
bacteria and/or eukaryotic cells with the agents to be tested or after competitive 
binding, cells were washed with HBSS and L  pneumophila added to wells of 6 
and 24-well plates and allowed to adhere to eukaryotic cells for 1 h.
Appropriate control organisms and cells were treated with HBSS. After the 
binding period, unattached organisms were removed by three-fold washings 
with HBSS and host-cell bound organisms assayed  by viable count and IFA 
methods a s  follows:
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Viable counts . After removal of non-adherent L. pneumophila eukaryotic 
cells were lysed by the addition of 1 ml of sterile distilled water. This procedure 
did not affect the viability of the bacteria a s  ascertained by viable count studies 
of similarly treated organisms. Bacterial counts were m ade on lysates from 
each of 10 separate  wells by inoculating 10fil in duplicate of appropriate
dilutions onto BCYEa plates. Plates containing 30 to 300 colonies after an
incubation period of 72 h were used to calculate average viable counts of 
lysates for each well as  previously described (91). Ratios of cfu/eukaryotic cell 
were determined by dividing average lysate values for each  well by the number 
of eukaryotic cells seeded  per well. These values were compared to untreated 
control values within each experiment for determination of the percent reduction 
of adherence following each treatment used.
Non-specific binding of organisms to the plastic culture plates was 
determined for each experimental trial. For every well, viable count estimations 
of unbound organisms contained in w ashes made following the 1 h incubation 
period for adherence assay s  were determined. This value was added  to the 
corresponding lysate value for the appropriate well and subtracted from the 
inoculum. The resultant figure was used to estimate the presence of bacteria 
non-specifically stuck to exposed plastic not covered by the cell monolayers. In 
multiple experiments, this value was found to be a  consistently small 
percentage of the inoculum. The level of nonspecific binding was found to be 
unaffected by bacterial or eukaryotic cell treatments and w as not altered by the
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addition of de-ionized water.
Immunofluorescence. Following bacterial or eukaryotic cell treatments 
and binding experiments, U937 and MRC-5 cells were fixed in 10% buffered 
formalin for 12 h, washed in HBSS, and treated in situ on the glass coverslips 
with a  1:100 dilution of rabbit anti-L. pneumophila antibody (see Appendix 4) for 
1 h at 37o C. Unbound globulin was removed with three-fold washings of 
HBSS. Cells were then treated with a  1 :200 dilution of goat anti-rabbit FITC 
conjugated antibody (Cooper Biomedical, Malvern, Pa.) for 1 h at 37° C. 
Unbound globulin w as removed by repeated washings and cells 
counterstained with 1% (w/) propidium iodide for 5 min. G lass coverslips were 
mounted in 1% (w/v) 1 ,4- diazobicyclo (2.2.2.) octane (DABCO) (Sigma 
Chemicals, St. Louis, Mo.) in glycerin onto microscope slides and viewed with 
an Olympus BH-2 epifluorescence microscope using an excitation filter emitting 
a  wavelength of 490 nm and a  barrier filter blocking wavelengths above 515 
nm. The number of fluorescing organisms bound to 200 eukaryotic cells w as 
determined and expressed  a s  adherent organisms/cell. These were compared 
to control values within each experiment to determine the percent reduction of 
adherence. Non-specific binding of labelled organisms to a reas  of g lass  not 
covered by eukaryotic cells was ascertained by IFA. Although this w as noted to 
be insignificant in all experiments, these  organisms were not counted in the IFA 
assay  for adherence to host cells.
3.4 Results
Adherence to U937 and MRC-5. Bacterial binding to U937 and
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MRC-5 cells is illustrated by IFA in plate 3.1 and binding curves for both cell 
lines are summarized in Figures 3.2-3.5. For each cell type, the use of 
approximately 5 x 108 cfu/ml a s  the inoculum gave adherence kinetics 
approaching saturation of the eukaryotic receptors. This was consistent for 
either U937 (Figures 3.2 and 3.3) or MRC-5 (Figures 3.4 and 3.5) cells as  
determined by both assay  techniques. The saturation points corresponded to 
an average cfu/cell ratio of 2.5 and 11 1or U-937 (Figure 3.2) and MRC-5 (Figure 
3.4) cells, respectively, a s  assayed by viable counts. IFA equivalent ratios were 
3.1 and 6.9 organisms/cell for U937 (Figure 3.3) and MRC-5 (Figure 3.5) cells, 
respectively. At this high inoculum level, marked non-specific binding to the 
plastic of culture dishes and glass coverslips were noted by both viable counts 
and  IFA. However, the use of an inoculum with 10-fold fewer organisms 
(approximately 5 x 107 cfu/ml) gave non-specific binding levels that were 
dramatically reduced. This inoculum was equivalent to about 100 bacteria/ 
eukaryotic cell (or 100 MOI) and approached the saturation point of eukaryotic 
receptors of both cell lines.
Inhibition of adherence studies. Bacterial trea tm en ts . Figures 3.6-
3.9 illustrate the percent reduction of adherence following modification of L  
pneumophila with the agents listed in Table 3,1. Prior treatment of L.
pneumophila with glutaraldehyde, p-galactosidase, chymotrypsin, lipase,
protease, trypsin and sodium metaperiodate all effected a  greater than 50% 
reduction in adherence to U937 cells a s  compared with controls in both viable 
count and immunofluorescence assays. For MRC-5 cells only bacterial
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treatments with glutaraldehyde, chymotrypsin, protease, trypsin and sodium 
metaperiodate effected a  similar response; i.e., unlike for U937 cells, lipase and
(3-galactosidase treatment did not significantly influence bacterial binding to
MRC-5 cells. Bacterial adherence or inhibition of binding to both U937 and 
MRC-5 cells w as consistently similar whether a ssayed  by viable count or IFA 
methods.
Eukaryotic treatment. Figures 3.10-3.13 illustrate the percent reduction in 
adherence following modification of U937 and MRC-5 cell surfaces with the 
agents  listed in Table 3.2. Concanavalin A, wheat germ agglutinin, sodium 
metaperiodate, nonidet P40, glutaraldehyde and formaldehyde reduced 
binding of L.pneumophila to treated U937 cells by greater than 50% (Figures
3.10 and 3.11). Similar results were obtained by viable count and IFA 
generated data. It was noted that none of the enzymatic treatments reduced 
bacterial binding to U937 cells. In addition, modification of U937 cell surfaces 
with cytochalasin B, a eukaryotic microtubule formation inhibitor, did not result 
in differences between treated and untreated cells a s  m easured by either a ssay  
technique. These  results were difficult to interpret but suggested that bacterial 
uptake by the phagocytic U937 cells may be independent of attachment since 
the difference between the two assays w as not great.
The percent reduction of adherence to MRC-5 cells following treatment 
with the modifiers listed in Table 3.2 are illustrated in Figure 3.12 and 3.13. 
Concanavalin A, wheat germ agglutinin, sodium metaperiodate, nonidet P40, 
glutaraldehyde and formaldehyde effected significant reductions in bacterial
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binding a s  m easured by viable counts and IFA. However, viable counts but not 
IFA indicated that lipase and chymotrypsin treatment of cells reduced 
adherence by greater than 50%.
In all eukaryotic treatments with either cell line assay ed  by both 
techniques, concanavalin A, wheat germ agglutinin, glutaraldehyde and 
formaldehyde were the strongest inhibitors of bacterial binding.
S u g a rs . Co-incubation of L  pneumophila with either cell line in the 
presence  of those sugars  listed in Table 3.3 are  illustrated in Figures 3.14-3.17. 
Of those  tested, no monosaccharide was able to significantly reduce bacterial 
binding to U937 or MRC-5 host cells. Viable count and IFA techniques yielded 
similar results for ail sugars tested.
3.5 Discussion.
The adherence of microorganisms to host cells a s  a  prelude to the 
d isease  process has  been well documented (8 ). A number of bacterial 
components, including pili and fimbriae, have been shown to mediate the 
specific attachment of microbes to eukaryotic cells (8 , 70, 116), but evidence 
has suggested  that th e se  and other structures may act concomitantly or 
sequentially (39, 131) in this process. In addition, the role of van der Waals, 
thermodynamic forces and hydrophobic interactions in the initial attachment 
and eventual binding of bacteria to cell surfaces is still unclear. The parameters 
for both an  effective bacterial binding assay and a  rationale for determining 
adherence were established. These  criteria were used to partially characterize 
the nature of "adhesins" involved in L. pneumophila adherence.
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The adherence curves indicated that a  specific interaction between L. 
pneumophila and both cell types occurred. Bacterial binding to eukaryotic 
receptors approached apparent saturation levels when an inoculum of 
approximately 108 cfu/ml was used  in adherence assays. However, this data 
required caution in interpretation as  increasing quantities of non-specific 
binding to plastic wells were noted to exceed acceptable levels at this point.
Determination of adherence as  m easured by viable count and IFA 
techniques yielded consistent and  corroborative results and provided evidence 
that a  lectin-like adhesin(s) associated with the surface of L. pneumophila was 
in part, responsible for mediating attachment to U937 and MRC-5 cells. 
Degradation and immobilization of bacterial surface proteins with enzyme and 
fixative treatments a s  well as periodate oxidation of microbial sugars 
significantly reduced L. pneumophila adherence to both types of host cells. That
lipase and (5-galactosidase treatment of bacteria prior to adherence
experiments significantly reduced adherence to U937 cells, but not to MRC-5 
implied that lipid and lactose moieties may also be important components in the 
bacterial binding process. Several gram-negative bacteria p o sse s s  lectin-like 
molecules associated with pili, fimbriae, or flagella which enable them to 
adhere to host cell surfaces {8 , 70, 120). L  pneumophila p o ssesses  
analogous bacterial appendages  (108 and Figure 3.1) which may facilitate 
bacterial binding by similar mechanisms. Isolation of these  structures in pure 
form for u se  a s  potential blocking agents in similar adherence experiments will 
further elucidate their role as adhesins.
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Treatment of eukaryotic cell surfaces with the lectins concanavalin A and 
wheat germ agglutinin substantially reduced bacterial binding an a  corroborated 
our results from the bacterial treatment trials. That oxidation of eukaryotic cell 
surface sugars with sodium metaperiodate inhibited bacterial binding further 
supported these  findings. However, co-incubation of bacteria and cells in the 
presence of mannose or N-acetyl glucosamine (sugars specific for 
concanavalin A and wheat germ agglutinin) failed to appreciably inhibit 
attachment. This may be due to the presence of dissacharides or complex 
oligosaccharides on the surfaces of the U937 and MRC-5 cells that contain the 
appropriate sub-unit monosaccharides specific for concanavalin A and  wheat 
germ agglutinin. Therefore, the addition of simple monosaccharides a s  
potential blocking agents in these experiments may not be recognized by L. 
pneumophila lectin-like surface molecules and consequently failed to reduce 
adherence. Use of dissacharides or oligosaccharides in similar competitive 
blocking studies may elucidate putative receptors for L. pneumophila.
However, determination ot the nature of th e se  "docking" sites by th e se  methods 
are  easily complicated by steric considerations such a s  the presence of 
disaccharide sugar receptors conjugated with proteins, lipids or other cell 
membrane moieties. In this study, efforts were focused on the bacterial 
component of L. pneumophila adherence to host cells.
That fixation of cell surfaces drastically reduced L. pneumophila binding 
to U937 and MRC-5 cells while treatment with proteolytic enzymes did not, may 
signify a  requirement for mobile, complex proteins or glycoproteins to facilitate
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the adherence of bacteria to these cells. In addition, oxidation of eukaryotic cell 
surface sugars  with sodium metaperiodate actively inhibited bacterial binding, A 
possible role for these molecules could be selective steric masking or exposure 
of receptors specific for adhesins on the surface of L. pneumophila. In addition, 
treatment with nonidet P-40 blocked adherence of L. pneumophila to both cell 
lines w hereas  similar treatment with lipase was generally not effective (reducing 
adherence to MRC-5 cells by 53% as  assayed by viable counts only). These 
results suggested  membranous lipid moieties as  possible components of 
eukaryotic receptors a s  well. It was clear from the compiled data that a  simple 
and uniform receptor system for L. pneumophila may not exist on the surface of 
U937 and  MRC-5 cells. Indeed, synergistic, sequential, steric and hydrophobic 
interactions between different membrane components of host cells may have a 
role in the recognition process and further complicate the elucidation of host cell 
receptors specific for L. pneumophila.
The cytochalasins inhibit the internalization processes  of eukaryotic cells 
and have been used to determine whether pathogens enter host cells by means 
of active invasion or phagocytosis. Elliott and Winn (36) have shown that L. 
pneumophila fails to actively penetrate cytochalasin-treated guinea pig alveolar 
m acrophages in vitro. However, the attachment of bacteria to phagocyte 
m em branes was not inhibited in these trials. In the present studies, adherence 
experiments following treatment of the macrophage-like U937 cells with 
cytochalasin B resulted in similar binding capacities a s  assayed by viable 
counts and  IFA when com pared to untreated controls. Given that viable counts
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measure attached and internalized organisms while IFA staining facilitate the 
detection of only bound bacteria these experiments indicate that significant 
numbers of legionellae were not phagocytosed during the one hour binding 
assay and that a  process of "uptake-independent-adherence" (UIA) occurred for 
L. pneumophila.
Caution should be exercised when extrapolating in vitro results derived 
from laboratory experimental conditions to the context of the clinical situation. 
Neither eukaryotic cell type used in this study were the natural host cell of L. 
pneumophila in human clinical disease. Although both are human cell lines, 
U937 cells are macrophage-like cells derived from a histiocytic lymphoma and 
may p o ssess  characteristics not resembling those of primary alveolar 
macrophages. MRC-5 cells are a  semi-continuous fibroblast cell from the lung 
and exhibit few of the properties of alveolar macrophages. Other potential 
factors include environmental differences that exist between cells propagated in 
vitro as com pared with those grown in vivo. Exposure to disparate nutritional 
sources, regulatory signals and other microorganisms could effect the 
expression of host target cell receptors. Similarly, varying nutritional conditions 
between the in vitro and clinical environment will most likely affect the growth of 
microorganisms and may alter expression of adhesins responsible for 
attachment to eukaryotic cells.
The d a ta  from these  studies offer evidence that a  lectin-like adhesin(s) 
mediates attachment to U937 and MRC-5 cells. The nature of this receptor(s) 
remains to be elucidated. Host cell receptors most likely consist of
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oligosaccharide and lipid structures that interact to form complex but as yet 
unresolved "docking site" for the organism. The finding that lectin-like adhesins 
occur on other gram-negative bacteria possessing appendages  such as  pili, 
fimbriae, or flagella in association with these adhesive molecules suggest that 
L. pneumophila may utilize similar attachment strategies. Studies using these 
and other fractionated bacterial structures as blocking agents along with wider 
c la sse s  of saccharides in adherence assay s  could further characterize or 
identify specific components responsible for mediating attachment. The 
elucidation of factors which contribute to the binding of L. pneumophila to host 
cells will increase our understanding of the pathogenic mechanisms used by 
this intracellular pathogen to initiate d isease  and may eventually influence the 
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Figure 3.1. Lenionalla pneumophila. Schematic representation of potential 
"adhesins" and eukaryotic cell receptors.
(Reproduced with kind permission from reference 38, Oldham and Rodgers, Zbl. 
Bakt. I Abt. Orig. A.)
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Table 3.1. Bacterial treatments prior to adherence a ssa y s








B-galactosidase 100 60 Degradation of
chymotrypsin 250 60 protein/sugar-containing
lipase 100 60 adhesins on surface of















10mM 30 Oxidation of carbohydrate 
moieties
5 7
Table 3.2. Eukaryotic cell treatments prior to adherence a ssa y s








Chymotrypsin 0.1 30 Degradation of enzyme
Lipase 100 30 sensitive receptors







Glutaratdehyde 0 .1% 10 Immobilization of protein-
Formaldehyde 1 .0 % 10 containing moieties




5mM 10 Oxidation of carbohydrate 
moieties





Concanavalin A 100ug/ml 60 Binds to m annose
Wheat Germ 
Agglutinin
100ug/ml 60 Binds to N-acetyl 
glucosamine
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Figure 3.2 Bacterial binding of L. pneumophila to U937 cells a s  m easured by 
viable counts of organisms released from lysed cells. Ratios of cfu per cell were 
calculated by dividing the average lysate value obtained from each inoculum by 
the average eukaryotic cell seed  per well. For this experiment the average cell 
s eed  equaled 5.7 x 105 cells/well. Bacterial attachment to eukaryotic cell 
receptors approached saturation when an inoculum of approximately 5 x 108 
cfu/ml was added to cell cultures (arrow). This corresponded to a  ratio of 2.5 
cfu/eukaryotic cell. Each point represents an average of three separate trials.
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Inoculum (cfu/ml)
Figure 3.3 Bacterial binding of L. pneumophila to U937 cells a s  m easured by 
IFA. The number of fluorescing organisms bound to approximately 200 
eukaryotic cells is expressed  as a  ratio of organisms/eukaryotic cell for each  
inoculum used. An inoculum of about 5 x 108 approached saturation of 
eukaryotic receptors (arrow). This corresponded to a  ratio of 3.1 
organisms/eukaryotic cell.
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Figure 3.4 Bacterial binding of L. pneumophila to MRC-5 cells a s  m easured by 
viable counts of organisms released from lysed cells. Ratios of cfu per cell were 
calculated by dividing the average lysate value obtained from each  inoculum by 
the average eukaryotic cell seed  per well. For this experiment the average cell 
s e e d  equaled 1 .6 X 105 cells/well. Bacterial attachment to eukaryotic cell 
receptors approached saturation when an inoculum of approximately 5 x 108 
cfu/ml was added to cell cultures (arrow). This corresponded to a  ratio of 11 




Figure 3.5 Bacterial binding of L. pneumophila to MRC-5 cells a s  m easured by 
IFA. The number of fluorescing organisms bound to approximately 200 
eukaryotic cells is expressed as  a  ratio of organisms/eukaryotic ceil for each 
inoculum used. An inoculum of about 5 x 100 approached saturation of 












Figure 3.6 Bacterial treatments, U937 cells. Percent reduction of L. 
pneumoohila binding to U937 cells a s  measured by viable count estimation of 
eukaryotic lysates following treatment of bacteria with th e  agents listed in Table 
3.1. Each value represents the average of 10 separate trials. Error bars 
indicate standard error of the mean for each  treatment.
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Figure 3.7 Bacterial treatments. U937 cells. Percent reduction of L. 
pneumophila binding to U937 cells as m easured  by counts of fluorescing 
organisms bound to approximately 200 eukaryotic cells following treatment of 











% reduction of adherence
Figure 3.8 Bacterial treatments, MRC-5 cells. Percent reduction ol L  
pneumophila binding to MRC-5 cells as  measured by viable count estimations 
of eukaryotic lysates following treatment of bacteria with the agents  listed in 
Table 3.1. Each value represents the average of 10 separate  trials as 
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Figure 3.9 Bacterial treatments, MRC-5 cells. Percent reduction of L, 
pneumophila binding to MRC-5 cells a s  m easured by counts of fluorescing 
organisms bound to approximately 200  eukaryotic cells following treatment of 
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Figure 3.10 Eukaryotic cell treatments, U937 cells. Percent reduction of L. 
pneumophila binding to U937 cells a s  measured by viable count estimations of 
eukaryotic lysates following treatment of host cells with the agents listed in 
Table 3.2. Each value represents the average of 10 separate trials. Error bars 
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Figure 3.11 Eukaryotic cell treatments, U937 cells. Percent reduction of L, 
pneumophila binding to U937 cells a s  m easured by counts of fluorescing 
organisms bound to approximately 200 eukaryotic cells following treatment of 
















1 0 2 0  3 0  40 50  60 70 8 0  90 100
% reduction of adherence
Figure 3.12 Eukaryotic cell treatments, MRC-5 cells. Percent reduction of L. 
pneumophila binding to MRC-5 cells a s  m easured by viable count estimation of 
eukaryotic lysates following treatment of host cells with the agen ts  listed in 
Table 3.2. Each value represents the average of 10 separate  trials. Error bars 
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Figure 3.13 Eukaryotic cell treatments, MRC-5 cells. Percent reduction of L  
pneumophila binding to MRC-5 cells a s  measured by counts of fluorescing 
organisms bound to approximately 200  eukaryotic cells following treatment of 
host cells with the agen ts  listed in Table 3.2.
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Figure 3.14 Competitive binding studies with sugars, U937 ceils. Percent 
reduction of bacterial adherence following co-incubation of L. pneumophila and 
U937 cells in the presence of monosaccharide sugars listed in Table 3.3 as 
m easured by viable counts of eukaryotic lysates. Concentration of added 
sugars was 100 mM. Each value represents the average of 10 separate  trials. 
Standard error of the mean is indicated for each treatment. None of the sugars 
used  in these experiments effected a  significant reduction of adherence.
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Figure 3.15 Competitive binding studies with sugars, U937 cells. Percent 
reduction of bacterial adherence following co-incubation of L  pneumophila and 
U937 cells in the presence of monosaccharide sugars listed in Table 3.3 a s  
measured by counts of fluorescing organisms bound to approximately 200  
eukaryotic cells. None of the sugars used in these  experiments effected a  
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Figure 3.16 Competitive binding studies with sugars, MRC-5 cells. Percent 
reduction of bacterial adherence following co-incubation of L. pneumophila and 
MRC-5 cells in the presence of monosaccharide sugars listed in Table 3.3 as  
m easured by viable counts of eukaryotic lysates. Concentration of added 
sugars was 100 mM.Each value represents the average of 10 separate  trials. 
Standard error of the mean is indicated for each treatment. None of the sugars 
used in these experiments effected a  significant reduction of adherence.
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Figure 3.17 Competitive binding studies with sugars, MRC-5 cells. Percent 
reduction of bacterial adherence following co-incubation of L. pneumophila and 
MRC-5 cells in the presence of monosaccharide sugars listed in Table 3.3 as 
m easured by counts of fluorescing organisms bound to approximately 200 
eukaryotic cells. Concentration of added sugars was 100 mM.
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©Plate 3.1 L. pneumophila binding to U937 and MRC-5 cells in an indirect 
immunofluorescence assay. Organisms are labelled with FITC (green) while 
eukaryotic cells are counterstained with propidium iodide (red), 
a) L. pneumophila attachment to U937 cells. Note incidence of bacterial binding 
to host cell surfaces (X 660), b) higher magnification of L. pneumophila binding 




The Effect of Antibiotics That Inhibit Cell Wall, Protein and DNA 
Synthesis on the Growth and Morphology of 
Legionella pneumophila 
4.1 Abstract
The response of L. pneumophila to cell wall, protein synthesis and DNA 
synthesis inhibitory antibiotics was examined by electron microscopy, MIC 
estimations and viable count assays. Cefotaxime, methicillin, rifampicin and 
ciprofloxacin, each used separately at 20 times their respective MIC values, 
showed activity against L. pneumophila in these studies. The cell wall 
inhibitors, cefotaxime and methicillin, effected the greatest bactericidal activity 
and induced the most extensive morphological changes. Organisms treated 
with th ese  antibiotics lost cytoplasmic contents through membranous lesions 
induced in their cell walls. In terms of ultrastructural dam age and loss of 
viability, the  protein and DNA synthesis inhibitors were less efficacious than 
antibiotics that acted on the microbial cell wall. Rifampicin treated cells 
po ssessed  irregular m em branes and were partially or fully lysed while 
ciprofloxacin induced abnormally elongated organisms with intermittently lysed 
and detached inner membranes. These results illustrated the ability of clinically 
putative antibiotics with diverse modes of action to affect microbial cytology at ■ 
the ultrastructural level a s  well as  the viability of L. pneumophila in vitro.
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4.2 Introduction
Leoionella pneumophila, the causal agent of a  fatal form of lobar 
pneumonia known as  Legionnaires' d isease, has been studied by negative 
stain, thin-section, freeze-etching, and scanning electron microscopy (105,
108). The response of this human pathogen to treatment with antimicrobial 
chemotherapeutic agents has been investigated using various in vitro and in 
Yim  techniques (19, 30, 35, 44, 45, 57, 60, 65, 83, 107, 109, 112, 128, 129, 
142). Although several antibiotics have excellent activity against Li 
pneumophila in vitro a s  a sse s se d  in minimum inhibitory concentration (MIC) 
studies, few show similar results in clinical trials.
Erythromycin is the current drug of choice for the treatment of 
legionellosis; however, inherent problems arise in its use. These include 
reports of relapse of infection, onset of phlebitis with intravenous antibiotic 
administration and potential complications associated with the development of 
bacterial resistance to therapy. In addition, studies in which Elliott and Rodgers 
(35) examined the morphological and growth response of L. pneumophila to 
erythromycin and ampicillin illustrated that erythromycin had limited bactericidal 
activity in vitro. Rifampicin has proven effective in clinical trials but is not used 
as  the sole therapeutic drug because of the high frequency with which 
resistance is induced. For these  reasons, a  number of other antimicrobial 
agents have been investigated as  potential alternatives for clinical use  in the 
treatment of legionellosis. Of those examined, the quinolone antibiotics have 
been the most promising. Ciprofloxacin, the best studied of this group, is a  lipid
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soluble antimicrobial which inhibits bacterial DNA gyrase and  has yielded 
encouraging results against experimental L. pneumophila infection in vivo (44, 
45, 128, 129).
In the present study, the morphological characteristics and growth 
response of L. pneumophila was examined following exposure to antimicrobials 
derived from three groups of antibiotics (bacterial cell wall, protein synthesis 
and DNA inhibitors). The evaluation of the efficacy of these drugs was 
determined using MIC estimations, viable count data and ultrastructural 
investigations.
4.3 Materials and Methods.
Reagent formulations and preparation along with detailed procedures 
are given in the appendices 1 and 3 .
Bacterial strain and growth conditions. L. oneumoohila 
serogroup 1, strain Nottingham N7 w as  isolated from a sputum sample of a  fatal 
c a se  of Legionnaires’ disease, was subsequently passaged  twice on 
bacteriological media and maintained fully virulent in a frozen state in serum 
sorbitol at -70° C. Cultures were grown on buffered charcoal yeast extract agar
supplemented with a-ketoglutarate (BCYEcc) (29) at 37° C for 48 h. Organisms 
were harvested from plates and inoculated into a-ketoglutarate enriched 
buffered yeast extract (BYEa) broth containing 10 g/l yeast extract (Difco), 10g/I 
ACES buffer (Sigma), 1 .Og/I a-ketoglutarate (Sigma), 0.4 g/l L-cysteine (Sigma) 
and 0.25 g/l ferric pyrophosphate (Sigma). The broth was adjusted to pH 6.9
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with KOH and filter sterilized through a  0.2pm filter to give a final concentration
of approximately 105 colony forming units (cfu)/ml. Organisms were incubated 
in static culture at 37°C and 5 ml aliquots removed at 4 to 6 h intervals to 
develop growth curves for this organism in the broth to be used for subsequent 
antibiotic activity studies.
Antibiotics. Dilutions of cefotaxime (sodium salt) (Hoechst-Roussel 
Pharmaceuticals), methicillin (sodium salt) (Sigma Chemical Company), 
rifampicin (Sigma Chemical Company), and ciprofloxacin (Miles 
Pharmaceuticals) were prepared in BYEa broth. Each antibiotic was added in
the mid-exponential phase of organism growth to give a  final concentration of 
20 times the MIC of each antimicrobial agent. Aliquots of 5 ml were removed 
after incubation for 6 and 24 h in the presence of antibiotics. Organisms were 
harvested by centrifugation at 600 g for 10 min, washed twice in broth and 
either serially diluted for viable counts or prepared for electronmicroscopy. 
Control samples of untreated organisms were harvested and prepared in the 
sam e manner.
Viable count technique. Bacterial counts were determined in 
triplicate by inoculating 10 pi aliquots of serially diluted antibiotic-treated
cultures onto BCYEa agar. Resultant cfu/ml were counted from those plates
containing 30 to 100 colonies as  previously described (91) to define the 
influence of th ese  antibiotics on bacterial viability.
Electron microscopy. Bacteria were fixed in 3% (v/v) glutaraldehyde
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in 0.05M sodium cacodyiate containing 10mM MgSC>4 (35 ). For negative stain
electron microscopy, 25 pi of each sample was mixed with an equal volume of
1% (w/v) phosphotungstic acid pH 6.7, and applied to 400 mesh formvar-carbon 
coated copper electron microscope grids. For scanning electron microscopy, 
samples were applied to specimen stubs, dehydrated in a  graded ethanol 
series, and treated with hexamethyldisilaxane (HMDS) (Polysciences, Inc.) 
(Warrington, Pa.) (87). Prior to examination, samples were coated with 20 nm of 
either gold/palladium with a target to specimen distance of 5 cm, at a  current of
15 mA for 4 min in a  Hummer V sputter coater. For thin-section electron 
microscopy, all samples were post-fixed in 1% (w/v) osmium tetroxide, 
dehydrated in an ethanol series and embedded in epon-araldite mixture. 
Sections of approximately 60 nm thickness were cut on an LKB Ultratome III 
with a diamond knife and stained with uranyl acetate 5% (w/v) for 1 min and 
lead citrate 0.4% (w/v) for 20 sec  (105, 108).
MIC determination. MICs were determined by the broth dilution 
method (133). Briefly, serial two-fold dilutions of each antibiotic were prepared 
in BYEa broth and inoculated with cultures in the mid-exponential phase of
growth to give a  final concentration of 105 cfu/ml. The broths were incubated for
16 h and the lowest concentration of antibiotic which inhibited growth w as taken 
a s  the MIC (Table 4.1)
4.4 Results.
Viability studies. MIC values for all antibiotics are shown in Table 4.1.
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The growth characteristics and effect on viability of L. pneumophila by the 
antibiotics investigated are illustrated in Figures 4.1-4.6 (data on ampicillin and 
erythromycin are from reference 35 with permission and are included for a 
complete comparative profile). L. pneumophila grown in BYEa broth, had a
mean generation time of 1.5 h. The bacterial cell wall inhibitors, cefotaxime and 
methicillin, effected the most rapid decline in viable counts during the first 6 h of 
treatment, while the remaining antibiotics also showed excellent activity against 
L. pneumophila throughout the course of these experiments. Of those tested, 
cefotaxime most effectively reduced organism viability and induced the most 
dramatic morphological changes  at the time intervals investigated.
Morphological studies. Untreated. Negative stain, scanning and 
thin-section electron microscopy studies of normal control organisms revealed 
the typical appearance of legionellae and confirmed the findings of others.
Most cells were 2-10 pm long and 0.25-0.5 pm wide. The bacterial surface of
normal cells w as rugose and ruffled in appearance. Organisms showed a cell 
wall structure consistent with that of gram-negative bacteria. A lipid bilayer, or 
cytoplasmic membrane, enclosed the cytoplasm which consisted of ribosomes, 
a  small number of intracellular vacuoles and a  fine skein of nuclear elements. 
The latter were distributed evenly throughout the bacterial cytoplasm. The outer 
membrane enveloped the periplasm which showed little structural evidence of a 
peptidoglycan layer (plate 4.1).
Cell wall inhibitors. Cefotaxime treatment. Cefotaxime at 20 times
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the MIC caused  extreme dam age to microorganisms. Incubation with this 
antibiotic for 6 h resulted in the formation of lesions and lytic points in the cell 
walls of a  greater number of bacteria than any of the antibiotics studied at this 
time period. Extrusion of the bacterial cytoplasmic contents through such lytic 
points was the most common feature noted. Bulbous vesicles were observed 
on the surface of cells and many organisms possessed  diffuse electron-lucent 
cytoplasmic contents. Extension of treatment with cefotaxime to 24 h resulted in 
an increase in dam age to these cells in terms of the degree of membranous 
lesions and vesicles induced in the cell surfaces as  well as  the number of 
organisms affected. In addition, many bacteria lacked either cytoplasmic 
contents or prokaryotic structure. The formation of spheroplasts w as not 
observed (plates 4.2 and 4.3).
Methicillin treatment. Organisms grown in the presence of 20  times the 
MIC of methicillin showed extensive morphological changes. Affected cells 
exhibited cell wall and membrane abnormalities and developed several lytic 
points through which the cytoplasmic contents extruded into the surrounding 
menstruum. Although many organisms appeared normal, spheroplast 
formation w as evident at this stage. Incubation with methicillin for 24 h induced 
a  greater degree  of cell wall and membrane dam age than the lesser incubation 
period. The outer membrane of the majority of organisms was found to have 
separated from the remaining cell wall and the development of small vesicles 
on the cell surfaces was evident. As a  consequence of lysis of the inner and 
outer membranes, a  loss of cytoplasmic material occurred (plates 4.4-4.S).
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Protein synthesis inhibitor. Rifamoicin treatm ent. Exposure of L* 
pneumophila to 20 times the MIC of rifampicin induced marked dam age to 
bacteria. Incubation for 6 h in the presence of this antimicrobial induced 
membrane dam age to the organism but this appeared less pronounced than for 
the other antibiotics examined. Separation of outer membranes from the 
remaining cell wall and breakage points in the inner m em branes were evident 
in affected microorganisms. In addition, the ribosomes of these  cells were 
enlarged, much increased in electron density and associated with a reas  of 
cytoplasmic clearing. Extended treatment with rifampicin elicited a  more 
pronounced effect in which lytic points in the membrane of cells and loss of 
intracellular contents led to eventual collapse (plates 4.9-4.12).
DNA inhibitor. Ciprofloxacin treatment. Organisms treated for 6 h with 
20 times the MIC of ciprofloxacin exhibited marked morphological changes.
The majority of cells were abnormally elongated forming filaments each of 
which possessed  centrally located "pinched zones" suggestive of arrested 
division. The inner membranes of many legioneilae were intermittently lysed 
and separated from the remaining cell wall material. In addition, the 
intracellular contents of cells were more densely packed due to an apparent 
overall increase in the size of individual ribosomes. Further exposure to this 
antibiotic induced dam age to 98% of the Legionella organisms present. 
Twisted, convoluted bacteria were found with depressed, partially collapsed 
a reas  on their cell surface. In addition, some organisms at this time had lost 
their intracellular contents through breakage points in the cell wall while others
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maintained the densely packed cytoplasmic appearance found in 6 h antibiotic 
treated organisms (plates 4.13-4.19).
Figure 4.7 shows the relative proportion of lysed and partially dam aged 
cells compared with those of normal morphology following antibiotic treatment 
for both 6 and  24 h and Table 4.2 summarizes the morphological findings.
4.5 Discussion
Erythromycin is the preferred drug for the treatment of Legionnaires’ 
disease. However, because  patients with severe illness often respond poorly to 
antimicrobial therapy, new antibiotics are being studied for use  as  alternate 
therapeutic regimens. In vitro screening of these potential agents  to determine 
the activity an d  mode of action of these antibiotics must be performed in order to 
evaluate subsequent in vivo and clinical trials. In the present study, the in vitro 
effect of clinically relevant antibiotics, including the new quinolone, 
ciprofloxacin, on the growth and morphology of L. pneumophila was examined.
Electron microscopy studies have been important for the delineation and 
understanding of antimicrobial activity against many pathogenic 
microorganisms (61, 77, 141). Elliott and Rodgers (35,107, 109) evaluated the 
morphological and growth response of L. pneumophila following exposure to 
ampicillin and erythromycin for 6 and 24 hours using electron microscopy, MIC 
determinations and microbial viable count data. In that investigation, ampicillin 
exhibited grea ter  bactericidal activity and induced more ultrastructural changes 
than erythromycin in vitro. Ampicillin treatment caused  the appearance of 
vacuole-like lesions in the cell walls of organisms which led to extensive
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bacterial lysis and collapse of legionellae while exposure of L. pneum ophila to 
erythromycin effected occasional breakage points in the cell wall along with 
cytoplasmic clearing, formation of membranous vesicles and some cell lysis.
In this study, all antibiotics tested were effective against L. pneumophila 
as a ssayed  by MIC data, the reduction in bacterial viable counts and 
morphological response induced. Methicillin showed extreme bactericidal 
activity against multiplying organisms in broth culture. This was confirmed by 
the morphological studies in which many lysed and empty cells were evident 
after 6 and 24 h exposure periods. Formation of spheroplasts following 
treatment with 1280 pg/ml of this antibiotic was demonstrated and confirmed
previous observations by Elliott and Rodgers of this phenomenon with another 
cell wall inhibitory antibiotic, ampicillin (35). These data suggested that the 
formation of minicell-like organisms and spheroplasts upon exposure to cell 
wall inhibitory antibiotics such a s  methicillin and ampicillin may constitute a 
mechanism by which osmotically protected legionellae survive within host cells 
and continue infection following reversion to vegetative forms upon 
discontinuation of therapy. Such findings may offer an explanation for the 
reported apparent "reactivation" infections due to L. pneumophila and may 
reflect ineffective killing of the organism in vivo in human lung.
Chan et al. (19) reported similar spheroplast formation for methicillin 
used at 100 pg/ml, but could not demonstrate this phenomenon with increased
doses of up to 1000 pg/ml of methicillin. It is possible that the addition of
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magnesium salts to the fixatives and buffers used  in the present study could 
have stabilized fragile bacterial membranes and may account for the 
differences in spheroplast detection.
Cefotaxime showed the greatest bactericidal activity and this resulted in 
the most rapid decline in numbers of viable organisms. Indeed, this third 
generation cephalosporin induced the greatest morphological changes in 
microbial cytology at either of the exposure times. These results conflicted with 
those of Chan et al. (19) who reported no morphological changes  in response 
to treatment of L. pneumophila with different doses  of this antibiotic. It was 
interesting to note that this drug failed to induce spheroplast formation by L. 
pneumophila although a  similar finding was reported following treatment of 
other gram negative bacteria with increased levels of cephalothin (88 ).
Although most Legionella species produce (3-lactamases, the p-lactam
antibiotics are most effective against actively dividing L. pneumophila cells in 
vitro. In this study, antibiotics were added in the mid-exponential phase of 
growth, which for L. pneumophila using the broth selected and an inoculum of 
105 cfu/ml was achieved 24 h into the growth cycle, to allow th ese  agents to 
function at their full capacity. Failure of Chan et al. (19) to detect similar 
morphological changes due to this antibiotic may have reflected the non- 
replicative status of the organisms subjected to antimicrobial treatment.
Ciprofloxacin and rifampicin showed effective bactericidal activity in 
viable count estimations at all the times studied. Despite showing the greatest 
activity in MIC assays, these  antibiotics induced only moderate structural
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dam age after short term exposure. However, such changes increased with 
treatment time. That bacterial viability was lost prior to the induction of 
extensive ultrastructural dam age probably reflected the mode of action of these  
antimicrobial agents against L. pneumophila cells in the exponential phase of 
growth.
Results from this and other studies (35, 107, 109) demonstrated that the 
cell wall inhibitory antibiotics were the most effective in terms of their ability to 
reduce L. pneumophila viability and induce morphological dam age in vitro. 
Although all the antibiotics investigated in this study showed in vitro 
antimicrobial activity against L. pneumophila, it has been reported that the 
aminoglycosides, cephalosporins, and penicillins including ampicillin and 
methicillin were clinically ineffective in the treatment of legionellosis (82). 
Because of its intracellular nature, L. pneumophila can avoid the effects of 
antimicrobial agents that lack the ability to penetrate host cell membranes. 
Indeed, it has been reported that ciprofloxacin, erythromycin and rifampicin (65, 
130) inhibit intracellular L. pneumophila growth while the (5-lactam antibiotics
such as  ampicillin, cefoxitin and cefotaxime do not (142). This most likely 
explains the efficacy of erythromycin and rifampicin in the clinical treatment of 
human legionellosis and emphasizes the need for further in vivo testing of 
ciprofloxacin as  a  potential alternative to current clinical therapeutic regimens.
That bacteria with apparently normal morphology were found following 
extended incubation with all antibiotics examined in this study and in similar 
experiments performed by Elliott and Rodgers (35) with ampicillin and
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erythromycin may offer further explanation for failure of current antimicrobial 
therapeutic protocols for the treatment of clinical Legionnaires' disease. In 
addition, these results considered in combination with reports of increasing 
incidence of bacterial resistance to standard antibiotic regimens indicated a 
continued need for thorough in vitro investigation of the response of pathogenic 
agents  to antimicrobial chemotherapy.
These data  illustrate the in vitro activity and mode of action of clinically 
relevant antibiotics for the treatment of Legionnaires' d isease. This information 
is necessary  to the understanding and evaluation of subsequent in vivo trials 
investigating the activity of these  agents for the treatment of experimentally 
infected animal systems and for potential therapy of clinical disease.
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1For viability and ultrastructural studies antibiotics were added to broth cultures 
at a  final concentration of 20 times the MIC, respectively.
2Data for ampicillin and erythromycin reproduced with permission (Elliott and 
Rodgers, J. Med. Microbiol., reference 35) and are included here to complete 
the comparative profile. Data were derived in a similar manner as  for the other 
antibiotics.
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Table 4.2 Morphological response of L. pneumophila following exposure to antibiotics for 6 and 24 
hours.
Feature Antibiotic
Cef Meth Amp1 Erv1 Rif Cipro 
6 h 24h 6 h 24h 6 h 24h 6 h 24h 6h 24h 6h 24h
formation of lesions in cell wall 
cytoplasmic clearing 
membrane vesicle formation 
spheroplast formation 
membrane abnormalities 
enlargement of ribosomes 
plasmolysed cells 
convoluted organisms
+ + + + +  + + + /- + + +
+ + + +  + + + - - - /+ +
+ + + + +  + + + - - - -
- - + + +  +
+ + + + +  + + + + + + +
+ + + + +
+ + + + + + + + + + + +
+ + + + -/+  + + + + + + +
o>
1From reference 35, Elliott and Rodgers, J. Med. Microbiol., with permission. Data included to 
complete comparative prolile.
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Figure 4.1 Growth of L. oneumoohila in BYEa broth ( ■  ■ ). The effect on
bacterial viability of cefotaxime ( ♦  ♦  ) added during the mid-exponential
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Figure 4.2 Growth of L. pneumoohila in BYEa broth ( ■  ■  ). The effect on
bacterial viability of methicillin ( ♦  ♦  ) added during the mid-exponential
phase of growth (arrow) is shown. This antibiotic was very effective at reducing 
bacterial viability.
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C o n tr o l
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t im e  (h)
Figure 4.3 Growth of L. pneumophila in enriched blood broth. The effect on 
bacterial viability of ampicillin added during mid-exponential phase of growth 
(arrow) is shown. This antibiotic effected a  rapid decline in viable counts but 
was not bactericidal for the entire bacterial population. Data reproduced with 
kind permission (Elliott and Rodgers, J. Med. Microbiol.. reference 35) and 
included here to complete comparative analysis. Growth of L  pneumophila in 
this broth had a  mean generation time of 2.0 h.
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Figure 4.4 Growth of L. pneumophila in enriched blood broth. The effect on 
bacterial viability of erythromycin added during mid-exponential phase of 
growth (arrow) is shown. This antibiotic was the  least effective in terms of 
bactericidal activity. Data reproduced with kind permission (Elliott and Rodgers, 
J. Med. Microbiol., reference 35) and included here to complete comparative 
analysis. Growth of L. pneumophila in enriched blood broth had a  mean 
generation time of 2.0 h.
9 5
C on tro l
R ifa m p ic in
1 00 8020 30 40 60 7050
time (h)
Figure 4.5 Growth of L. pneumophila in BYEa broth ( ■  ■  ). The effect on
bacterial viability of rifampicin ( ^  ) added during the mid-exponential 
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Figure 4.6 Growth of L. pneumophila in BYEa broth ( ■  ■  ). The effect on
bacterial viability of ciprofloxacin {^  ♦  ) added during the mid-exponential
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Figure 4.7 Proportion of bacterial cells showing normal morphology ( Q ) and 
those dam aged $ H )  after exposure for 6 or 24 h to the various antibiotics at 20 
times their respective MIC values. Percentages were calculated from counts of 
100 or more cells for each agent and for each treatment time. Data in boxed 
area  is reproduced with permision (Elliott and Rodgers, J. Med. Microbiol., 
reference 35) and is included for the purposes of comparison.
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Plate 4.1 Untreated, control Legionella organisms showing normal 
morphology. The bacterial surface is ruffled and the cell wall structure is 
com posed of a  double track membrane with little visual evidence of a 
peptidoglycan.
a) negative stain (X 18,000), b) scanning (X 30,000), c) thin-section (X 40,000). 
Bars=0.5 pm.
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Plate 4.2 L. pneumophila organisms exposed to cefotaxime for 6 h.
a) note bulbous vesicles on the surface of the organism, scanning (X 20,000),
b) organism showing loss of intact membrane structure surrounding diffuse, 
electron-lucent cytoplasmic contents, thin-section (X 40,000), c) bacterium with 
advanced membrane damage and associated loss of cytoplasm, thin-section 
(X 60,000). Bars=0.25 \im.
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Plate 4.3. Legionellae exposed to cefotaxime for 24 h. 
a) formation of lytic points (arrow) in the bacterial cell wall, negative stain 
(X16,000), b) collapsed organism with abnormal surface structure, scanning 
(X 30,000), c) plasmolyzed organism with loss of prokaryotic structure, (thin-
section (X 80,000). a, b Bars=0.5 pm, c Bar=0.25 pm.
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aPlate 4.4 L. pneumophila exposed to methicillin for 6 h. 
a) L. pneumophila organism with breakage point in cell wall (arrow), negative- 
stain (X 16,000), b) advanced s tage of lysis-cytoplasmic contents extruding 
through lytic point in the cell wail of an organism, negative-stain (X 18,000). 
Bars=0.5 pm.
1 0 2
Plate 4.5 Legionellae exposed to methicillin for 6 h.
a) dam aged  bacterial cells surrounding an apparently normal cell, thin-section 
(X 30,000), b) spheroplast formation is evident alongwith deformed and normal 
cells, thin-section (X 40,000). Bars=0.25 pm.
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Plate 4.6 L. pneumophila exposed to methicillin for 6 h.
a) severely dam aged cells with abnormal membrane distortion (arrow), thin-
section (X 40,000), b) plasmolyzed organism with pinching and ballooning of
membranes, thin-section (X 80,000). Bars=0.25 pm.
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Plate 4.7 Legionella organisms exposed to methicillin for 24 h. 
a) note loss of cytoplasmic contents through advanced lytic point in bacterial 
cell wall (arrow), negative-stain (X 12,000), b) induction of numerous blebs on 
the microbial surface, scanning (X 20,000). Bars=0.5 pm.
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Plate 4.8 L. pneumophila exposed to methicillin for 24 h. 
a) complete loss of bacterial cytoplasmic contents with extreme damage to the 
microbial cell walls, thin-section (X 40,000), b) organism devoid of cytoplasm 
with associated inner and outer membrane separation, thin-section (X 40,000). 
Bars=0.5 pm.
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Plate 4.9. Organisms exposed to rifampicin for 6 h.
a) note numerous breakage points in the cell wall and loss of cytoplasm from 
cell (arrows), negative-stain (X 16,000), b) extrusion of cytoplasm w as evident 
(short arrow) as  well a s  regions of bacterial collapse (long arrow), scanning (X
25,000). Bars=0.5 pm.
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Plate 4.10 L. pneumophila exposed to rifampicin for 24 h. 
a) darkly staining surface lesions and numerous small vesicles present, 
negative-stain (X 16,000), b) distorted, partially collapsed organisms, scanning 
(X 15,000), c) disruption of outer membrane and increased size and density of 
ribosomal content of cells, thin-section (X 70,000). 
a, b Bars=0.5 pm, c  Bar=0.25 pm.
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Plate 4.11 Organisms exposed to rifampicin for 24 h. Note localized zones of 
increased density and size of ribosomes within cytoplasm as  well as  distorted 
membrane structure of cells (arrow), thin-section (X 34,000). Bar=0.25 pm.
Plate 4.12 Organisms exposed to rifampicin for 24 h. Increased density of 
cytoplasmic contents is evident in addition to separation of cell walls from 
remaining cell contents, thin-section (X 34,000).
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Plate 4.13 L. pneumophila exposed to ciprofloxacin for 6 h. 
a) darkly staining lesions in cell wall of a  partially collapsed organism, negative- 
stain, (X 24,000), b) convoluted organism with centrally located pinched zone, 
scanning (X 20,000). Bars=0.5 pm.
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Plate 4.14 L. pneumophila exposed to ciprofloxacin for 6 h. Note severely 
deformed cell (arrow) with a reas  of cytoplasmic clearing and abnormal 
membrane structure, thin-section (X 34,000). Bar=0.25 urn.
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Plate 4.15 L. pneumophila exposed to ciprofloxacin for 6 h. Abnormal 
distribution of ribosomes alongwith areas  of localized clearing within the 
bacterial cytoplasm of cells, thin-section (X 40,000). Bar=0.25 pm.
Plate 4.16 Legionellae exposed to ciprofloxacin for 6 h. Note vesiculation of 
bacterial cytoplasm (arrow) and  increased size and density of ribosomes, thin- 
section (X 60,000). Bar=0.25 pm.
Plate 4.17 L. pneumophila exposed to ciprofloxacin for 6 h. Single cell showing 
very d e n se  ribosomal contents within bacterial cytoplasm, thin-section 
(X 60,000). Bar=0.25 ^m.
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Plate 4.18 L. pneumophila exposed to ciprofloxacin for 24 h. 
a) twisted, convoluted organism with multiple pinched zones, negative-stain (X
12,000), b) filamentous, twisted organisms are evident, scanning (X 10,000), c) 
partially collapsed organism with centrally located pinched zone, scanning
(X 34,000). a, b Bars=0.5 p.m, c Bars=0.25 urn.
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Plate 4.19 L  pneumophila exposed to ciprofloxacin for 24 h. Organisms 
showing various types of morphological response to treatment. Som e cells 
have lost their cytoplasmic contents (short arrow) while others exhibit increased 
ribosomal density (long arrow). Note twisted, abnormally shaped cell 
morphologies, thin-section (X 24,000). Bar=0.5 pm.
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Section V
Pathogenesis, Pathology and Chemotherapy of Experimental 
Legionella pneumophila Infection in the Chick Embryo
5.1 Abstract
The pathogenicity of Legionella pneumophila, serogroup 1, strain 
Nottingham N7, was a sse s se d  in terms of LD50 data  and the ability of the 
organism to induce histopathoiogical and ultrastructural lesions in the fertile 
hen's egg. Histological examination of embryo organs after inoculation with 1 , 
10 , 100 and 1000 times the yolk sac  LD50 revealed a  disseminated infection. 
Systemic spread  of the organism resulted in the appearance of pathological 
lesions and the generation of edema fluid. These were particularly severe  in 
the liver, heart, spleen and kidney. Electron microscopy of the pathology 
induced in organs of chick embryos previously infected with 100 times the 
YSLD50 of L. pneumophila confirmed these observations. Subtle pathological 
changes were noted three days post-inoculation while more extensive cellular 
and sub-cellular necrotic changes occurred at four days post-inoculation. The 
infection elicited an inflammatory cell response that consisted of 
polymorphonuclear leucocytes and lymphocytes. Selected antimicrobial 
agents were investigated in therapeutic studies for their capacity to ameliorate 
or control d isease  processes  in this test system. Of those examined, 
ciprofloxacin was most effective at reducing or reversing the incidence of
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lesions in these  tissues and for prolonging embryo viability. Rifampicin, and to 
a  lesser degree, erythromycin and doxycycline, also showed antimicrobial 
activity in these  in vivo trials. These results illustrated the efficacy of the fertile 
hen’s  egg as  a  useful alternative in vivo assay  system for the evaluation of 
clinically putative antimicrobial agents in the treatment of Legionnaires' 
d isease. In addition, this study demonstrated the superior antimicrobial activity 
of ciprofloxacin in the treatment of experimentally induced Legionella infections.
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5.2 Introduction
L- pneumophila is the etiological agent of legionellosis which in the 
severe pneumonic form presents as  Legionnaires’ d isease (85). Despite the 
accumulation of considerable data  describing the invasive nature of the 
microorganism, the pathogenic mechanisms by which this gram-negative rod 
causes infection are  not well understood. In human d isease  and experimental 
animal infections, the legionellae are facultative intracellular pathogens which 
survive and  replicate within alveolar macrophages.
Although primarily recognized as a  pneumonic illness, Legionnaires' 
disease has  been shown to produce a widespread bacteremia alongwith the 
appearance  of soluble L. pneumophila antigen in clinical samples of serum and 
urine (12) in association with extrapulmonary pathology (13, 115). Multi-organ 
inflammatory lesions due to Legionella bacteremia are not common but have 
been described (24). Because Legionnaires' d isease first presents a s  a  classic 
pneumonic infection, the extra-thoracic aspects  of the d isease  have been 
overlooked, but it is evident that the serious pathological sequelae that result 
from L. pneumophila infection may play a larger role in the overall d isease  
process than was previously suspected.
Numerous antibiotics with different m odes of action have shown activity 
against L. pneumophila in vitro (30, 35, 60, 109, 112, 123). However, many of 
these antibiotics with effective minimum inhibitory concentrations (MIC) are 
reported a s  ineffective in the treatment of Legionnaires' d isease  (82) while 
others such  as erythromycin, rifampicin, and to a  lesser extent, the tetracyclines
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have been efficacious in therapy (2). Erythromycin is considered the drug of 
choice for Legionnaires' d isease but variable clinical responses in patients to 
this antibiotic and problems associated with low dose  or intravenous 
erythromycin therapy have been reported (62). Consequently, other therapeutic 
options are currently sought.
The quinolones are  antimicrobial agents that effectively inhibit bacterial 
DNA gyrase activity. One member of this group, ciprofloxacin, is a  promising 
new lipid soluble antibiotic with broad spectrum activity and the ability to 
penetrate eukaryotic cells. This antibiotic has few side-effects, offers oral 
bioavailability, achieves high tissue concentrations and  has been used 
successfully in the treatment of various urinary and respiratory tract infections. 
Ciprofloxacin has been shown to be very active against L. pneumophila in vitro 
(60, 65) and in experimental Legionella infections of guinea pigs (44, 45, 135).
Because treatment of human legionellosis often com m ences well after 
onset of d isease, controlled clinical studies exploring the use of alternative 
chemotherapeutic agents are difficult to perform and force researchers to 
depend on animal studies for data accumulation. Although in vivo testing of 
antibiotic efficacy in guinea pigs has thus far correlated well with clinical data, 
investigators using this animal system for these studies require specialized 
equipment, animal laboratory facilities, specialized expertise, and, according to 
current regulations, qualified staff, animal care and u se  permission, and in 
som e countries animal licenses. In addition, the cost and availability of these 
animals limits the use of significant numbers in experiments and makes
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interpretation of data difficult. It is clear that the ability to test alternative 
therapeutic regimens for the treatment of Legionnaires’ d isease has become 
increasingly important and necessitates the development of a simplified and 
reproducible in vivo antimicrobial assay system.
Lewis et al. (83) introduced the use of embryonate eggs to examine in 
vivo prophylactic and post-infection antibiotic therapy of experimental 
legionellosis following the initial outbreak of Legionnaires' d isease in 
Philadelphia in 1976. This study evaluated antimicrobial therapy based  on the 
ability of antibiotics to reduce mortality rates of infected embryos and yielded 
results in keeping with clinical findings. In the present study, the chick embryo 
w as used to delineate the baseline histological and ultrastructural pathology 
associated with the progression of experimental infection in this animal with L. 
pneumophila in order to determine the therapeutic value of antimicrobial agents 
introduced into this animal following experimental infection. Results from these 
investigations were used to evaluate the chick embryo a s  an alternative in vivo 
assay  system for the testing of new and/or putative antimicrobial agen ts  in the 
treatment of human legionellosis. In addition, the quinolone antibiotic 
ciprofloxacin w as examined for its chemotherapeutic activity and compared with 
clinically relevant antibiotics for its effectiveness at regulating infection in the 
chick embryo animal system. Elucidation of the mechanisms of pathogenesis 
and  growth of L. pneumophila in this in vivo host system and the role of 
antimicrobial therapy in the d isease process may have an impact on current 
procedures for the maintenance and care of patients with legionellosis.
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5.3 Materials and Methods.
Reagent formulations and preparations along with detailed procedures 
are given in Appendices 1 ,2 ,3 ,  and 4.
Preparation of bacterial inocula. L. pneum ophila, serogroup 1 , 
strain Nottingham N7, was isolated from the sputum of a fatal c a se  of 
Legionnaires' d isease , subsequently passaged  twice on bacteriological media 
and maintained frozen at -70° C in 10% serum with added 1% sorbitol. Thawed 
aliquots were grown at 37°C on buffered charcoal yeast extract agar enriched
with L-cysteine, ferric pyrophosphate and a-ketoglutarate (BCVEa) (29) and
incubated aerobically for 48 hours. Organisms were harvested in 5 ml 
phosphate buffered saline pH 6.9 (PBS) to give a  density equivalent to 108 
colony forming units (cfu)/mi as  determined by a  Klett-Summerson photoelectric 
colorimeter. Organism mass, expressed in terms of viability, w as  determined in 
duplicate a s  cfu on BCYEa to confirm opacity data.
Egg type, incubation, inoculation route and determination of 
LD5 0 s. Antibiotic free, fertile White Leghorn hens' eggs (UNH Poultry Farm) 
were incubated at 36°C in a  humid atmosphere. Organisms were introduced 
into eggs  by four inoculation routes: allantoic and amniotic sa c s  (at 10 days of 
embryo incubation), chorioallantoic membrane (CAM) and yolk sac  (at 7 days of 
embryo incubation) (Figures 5.1 and 5.2). Sixty embryonate eggs  were used for 
each inoculation route. Serial 10-fold dilutions of L. pneumophila in PBS were 
made and those ranging from 101 to 106 cfu/ml were inoculated at a  rate of 10
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eggs per dilution. Inoculated eggs were incubated and candled twice daily to 
check for embryo viability. Mortality and protection experiments were performed 
three times and the LD50 for each inoculation route was determined from the 
averaged mortality data by the method of Reed and Muench (101).
Recovery of organisms and histopathoiogy studies. Organism 
m ass  was calculated as  described and the inocula adjusted to give inoculation 
d oses  equivalent to 1, 10, 100 and 1000 times the yolk sac  LD50 {YSLD50).
Each multiple dose  LD50 of L. pneumophila was inoculated into the yolk sacs of 
fertile eggs and these  were harvested at 24 hour intervals from one to eight 
days post-inoculation. Organ samples including liver, heart, spleen and kidney 
were removed aseptically from embryos, rinsed thoroughly in PBS and 
weighed. Organs were homogenized in a  Sorval Omni Mixer, serially diluted 
and aliquots inoculated onto BCYEa for viable count assay. Colony counts
were expressed a s  cfu/gram of tissue and were calculated for each organ at 
each time interval in triplicate. Similarly inoculated and control eggs were 
harvested and whole embryos a s  well as  samples of liver, heart, spleen and 
kidney were fixed in 10% buffered formalin and em bedded in paraffin wax in a 
Lab Tek Tissue Processor. Four micron thick sections were cut, deparaffinized 
and routinely stained with hematoxylin and eosin for histopathological 
examination.
Immunofluorescence. Deparaffinized tissue sections and tissue 
homogenates were incubated with a  1 in 50 dilution of rabbit anti-L.
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pneumophila serum, followed by incubation with a 1 in 200 dilution of FITC- 
conjugated goat anti-rabbit serum  (Cappel Laboratories, Malvern, Pa.). All 
labelling steps were followed by 3-fold washings in PBS to remove unbound 
globulins.
Electron m ic ro sco p y  s tu d ie s .  Eggs were inoculated with 100 times 
the YSLD50 by the yolk sac route, and the embryo organs, liver, heart, spleen 
and kidney, harvested at 24 h intervals and prepared for electron microscopic 
examination. Tissue samples were rinsed in 0.1 M cacodylate buffer, pH 7.2 
(CB) fixed in 3% (v/v) glutaraldehyde in CB for 24 hours, post-fixed in 1% (w/v) 
osmium tetroxide (OSO4 ) in CB for two hours and dehydrated in a  graded 
ethanol series. Samples were embedded in an epon-araldite resin mixture and 
polymerized for 24 hours at 60° C (105, 108). Thin sections, cut on an LKB 
Ultratome III with a  diamond knife, were stained with 5% (w/v) uranyl acetate 
and 0.4% (w/v) lead citrate and examined by transmission electron microscopy 
in a  Hitachi H600 electron microscope used  at 80kV.
Antibiotic therapy studies. MIC values were calculated for 
ciprofloxacin (Miles Pharmaceuticals, West Haven, Ct.), erythromycin, 
doxycycline and rifampicin (Sigma Chemicals, St. Louis, Mo.) by a  standard 
agar dilution technique (133) using BCYEa. For these experiments, eggs were 
infected by the yolk sac  route with 100 times the YSLD50 of L. pneumoohila.
For histopathological studies, one or ten times the MIC of each  of the four 
antimicrobial agen ts  were administered intra-allantoically at one day post­
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inoculation. Mortality data were calculated with time for each antibiotic and 
bacterial viable counts determined from embryo organ homogenates. Similar 
samples were harvested and prepared for histological examination to a s se s s  
the ability of each antibiotic to inhibit either an inflammatory cell response or the 
development of pathological lesions in embryo organs.
Antibiotic therapy of chick embryos was commenced at three days post­
infection for electron microscopic investigations. This schedule was selected 
because  electron microscopic studies of untreated control samples showed that 
this time interval allowed for the earliest expression of ultrastructural 
pathological lesions to develop after the introduction of L. pneumophila into the 
chick embryo. In such treatments, 10 times the MIC levels of each of the four 
antibiotics were administered intra-allantoically and organ sam ples of liver and 
kidney from viable embryos were harvested for electron microscopy at four and 
eight days post-inoculation (one and five days post-therapy, respectively).
5.4 Results
Pathogenesis. The LD50 values for L. pneumophila introduced into 
the embryonate egg were determined and are illustrated in Table 5.1. The 
inocula required to induce embryo death ranged from 1.4 X 102 cfu/ml for the 
amniotic sac  to 5.5 X 10* cfu/ml for the allantoic sac. The LD50 studies 
demonstrated that those inoculation routes which accessed  the immediate 
environment or the nutritional source of the embryo required lower organism 
numbers to induce fatal infections compared with more peripheral routes.
Inoculation of multiple doses of the YSLD50 into fertile hens’ eggs
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resulted in dissemination and growth of Legionella organisms in the liver, heart, 
spleen and kidney. A tissue response and dose effect w as observed in that 
viable counts on harvested organs of embryos infected with 1 or 10 times the 
YSLD50 revealed that exponential bacterial growth began at four days post­
inoculation in the liver and heart but after five days in the spleen and kidney 
(Figures 5.3 and 5.4). In addition, bacterial assay s  of organs from embryos 
inoculated with 100 and 1000 times the YSLD50 showed that organism growth 
began at four days post-inoculation in all examined organs (Figures 5.5 and 
5.6). Microbial assay  of tissues at eight days post-inoculation with 1000 
YSLD50 yielded counts ranging from 3.3 X 104 to 9.9 X 105 cfu/gram in the 
kidney and liver, respectively (Figure 5.6). Organism concentration in organs 
was highest in the liver and lowest in the kidney irrespective of the multiple 
dose used  as  inoculum.
Histopathology. Gross examination of the organs of embryos infected 
by various routes of inoculation with multiple d o ses  of the YSLD50 showed no 
ostensible lesions. Inoculated CAMs failed to demonstrate visible pocks or 
pathological changes. Following yolk sac inoculation, histopathological 
examination on organs of embryos infected with 1 , 10 , 100 and 1000  times the 
YSLD50 revealed pathological changes in the liver, heart, spleen and kidney 
and were most evident in regions rich in blood vessels (plates 5.1-5.5). With 
inocula of 1 , 10, or 100 times the YSLD50 an inflammatory cell response 
appeared simultaneously at five days post-inoculation in all organs examined
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but at four days following administration of 1000 times the YSLD50. At this 
stage, congestion of the blood vessels within tissues were most evident (plates 
5.1 -5.2). Heart tissue showed marked vascular congestion with evidence of an 
edem atous response (plate 5.2). In the kidney, pathological changes in the 
glomeruli, with an associated cell exudate, were evident as compared with the 
relatively undam aged convoluted tubules (plate 5.4).
Histopathological examination of sections at higher magnification 
showed degenerative in each organ typified by breakdown of cell and nuclear 
membrane structure, loss of cell components, and margination of nuclear 
chromatin. Darkly staining PMNLs and leucocytes were also common (plate 
5.5). These results are summarized in Table 5.2.
Immunofluorescence. The presence of L. pneumophila organisms in 
situ in tissue sections and homogenates was confirmed by specific 
immunofluorescence. Labelled organisms were visualized along with tissue 
dam age  in liver, heart, spleen and kidney sections of embryos previously 
inoculated with multiple doses  of the YSLD50.
Ultrastructural pathology. Electron microscopic examination of the 
liver, heart, spleen, and kidney of infected chick embryos revealed extensive 
pathological d am age  at the cellular and sub-cellular levels. These  
observations are  summarized in Table 5.3. The ultrastructural tissue damage 
induced by the organism was similar in all organs examined and the earliest, 
most tenuous pathological changes  were observed at three days post­
inoculation. Mitochondrial dam age was evident at this time (plate 5.6 and 5.7).
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Major ultrastructural changes occurred at four days post-inoculation and 
consisted of extensive degenerative changes which included fatty degeneration 
and cytoplasmic clearing. These changes were characterized by ballooning 
and breakdown of the cellular and nuclear membranes, nuclear clearing, 
margination of chromatin material, and cytoplasmic vesiculation (plate 5.8). A 
hemolytic process (plate 5.9) was evident in these tissues. During latter stages 
of the infection, many lysed, swollen or apparently empty mitochondria were 
distributed throughout the cytoplasm of affected cells. At this stage, the nuclei of 
many cells exhibited pyknosis or karyolysis (plate 5.10-5.12). In addition, 
lysosomal bodies were present within cells presumably involved with autolysis 
of these tissues. Occasionally, small numbers of legionellae were observed 
within cells of embryo organs (plate 5.13).
Antibiotic therapy studies. The MICs of ciprofloxacin, doxycycline, 
erythromycin and rifampicin for L. pneumophila are shown in Table 5.4. Of the 
four antibiotics, ciprofloxacin at 10 times the MIC proved most effective in 
delaying tissue dam age and preventing an inflammatory cell response prior to 
eight days post-inoculation a s  a s sessed  by histopathological examination. 
Erythromycin, doxycycline or rifampicin effected a delay in the  development of 
these  lesions, but their effect was much less pronounced. These results are 
shown in Table 5.4. Only embryos protected with ciprofloxacin survived to term. 
In addition, the efficacy of these  antibiotics was evaluated in bacterial viable 
count assays  performed on organs of embryos previously infected eight days  
previously with 100 times the YSLD50 of L. pneumophila. Results are shown in
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Figure 5.7. At 10 times their MIC, ciprofloxacin was more efficient at reducing 
organism numbers in these tissues than either erythromycin or rifampicin.
Figure 5.8 shows the results of embryo viability after inoculation with 100 times 
the YSLD50 of L  pneumophila with administration 24 hours later of 10 times the 
MIC levels of ciprofloxacin, erythromycin or rifampicin. Ciprofloxacin gave the 
highest percentage of embryo survival throughout the trials. Eight days post­
inoculation the survival rate for embryos protected with ciprofloxacin w as 83% 
compared with rifampicin at 33% or erythromycin at 10%. By 14 days post­
inoculation all rifampicin or erythromycin treated embryos had succumbed to 
infection.
Ultrastructural observations of infected embryo organs treated three days 
subsequently with 10 times the MIC of these  antibiotics showed similar changes 
and are summarized in Table 5.5. Only viable embryos were processed for 
electron microscopic examination. Ultrastructural tissue dam age in 
erythromycin (plate 5.14) and doxycycline (plate 5.15) treated embryos w as less 
severe than unprotected tissues at four days post-inoculation. Indeed, the 
cellular changes at this stage in the presence of erythromycin were similar in 
appearance to those at day three of infection in the absence  of antibiotic. 
Tissues from rifampicin treated embryos also showed less  damage than 
controls and were comparable at four and eight days post-inoculation (plates 
5.16 and 5.17). However, tissues from ciprofloxacin treated embryos were 
found to be consistently less dam aged at eight days than at four days post­
infection (plates 5.18 and 5.19) indicating that the degenerative process
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associated with infection at the ultrastructural level had been reversed.
5.5 Discussion
In keeping with current pressures and legislation to reduce vertebrate 
animal use in research and diagnosis, the self-contained embryonate hen's egg 
offers an alternative in vivo antibiotic assay system for L. pneumophila. Eggs 
are relatively easy to handle, inexpensive, and can be used in sufficiently large 
numbers to test each antibiotic so a s  to give significant assessm en t levels 
normally unattainable with other laboratory animals. In addition, no specialized 
animal facilities, equipment, personnel or licenses a re  required.
The LD5o studies revealed the high degree of pathogenicity of L  
pneumophila for this animal. These findings reflected the relative few numbers 
of microorganisms required to achieve these mortality data and illustrated the 
extreme infectious nature of the bacterium for the chick embryo and  its tissues. 
The rapid growth of L. pneumophila in the liver, heart, spleen and  kidney 
following inoculation with multiple d o ses  of the YSLD50 indicated that growth of 
the organism in the chick embryo was characterized by a bacteremia with 
satellite infections in these  organs. Microbial a s say s  also revealed that 
irrespective of the inoculum dose, extensive organism growth occurred within 
organs all organs examined, most notably in the liver but to a  lesse r  degree in 
the kidney. These data supported similar observations by other workers that 
organisms were found within the extrapulmonary organs of hum ans and 
animals previously infected with L. pneumophila.
Correlation exists between human legionellosis and experimental
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infections in various animal models. Pyrexia, antibody production, cell- 
mediated immunity and bacteremia have been demonstrated in various 
laboratory animals. In addition, the production of inflammatory cells in response 
to experimental and natural infections with the organism is often similar and 
consists of a  mixed infiltrate of PMNLs and macrophages. Histopathological 
examination of the liver, heart, spleen and kidney of the chick embryo following 
inoculation with multiple doses  of L. oneumoohila revealed the simultaneous 
appearance of vascular cells in all organs and suggested a  large scale 
inflammatory cell response consisting primarily of PMNLs and lymphocytes.
Experimental infection of fertile hens' eggs with L. pneumophila elicited 
severe cellular and sub-cellular pathological changes in all embryo organs 
examined by electron microscopy. That ultrastructuraf tissue dam age was 
found to be similar and occurred synchronously three days post-inoculation in 
these  organs supported histopathological observations of a  systemic-type 
infection in this animal (128). The ultrastructural appearance of tissues of 
infected embryo organs was comparable to similar features exhibited in human 
legionellosis (20, 21, 30, 105, 111).
Although L. pneumophila is sensitive to a  variety of antimicrobial agents 
in vitro, the ability of this pathogen to replicate intracelluiarly limits the use of 
many of th ese  agents in vivo. Antibiotics which have been used  successfully in 
treatment include erythromycin, rifampicin and the tetracyclines. Animal 
experiments with guinea pigs previously exposed to aerosol suspensions of L. 
pneumophila and treated with clinically proven antibiotics readily demonstrated
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the efficacy of rifampicin and to a lesser extent erythromycin. Effective 
antimicrobial agents were able to decrease  mortality and clear viable L. 
pneumophila from the lungs but only rifampicin was able to reverse 
histopathological lesions (57). Similar results were obtained using L. 
pneumophila infected fertile hens' eggs in which mortality da ta  was reduced by 
treatment with rifampicin and erythromycin administered either prophylactically 
or post-infection (83). To date, additional antimicrobial investigations have not 
been performed to corroborate and extend these results.
Ciprofloxacin has shown excellent in vitro activity against L. pneumophila 
in preliminary studies with agar and broth dilution tests as  well as  cell cultures 
(65). Effective ciprofloxacin treatment of experimental Legionella infection in 
guinea pigs has also been demonstrated. In these  studies, ciprofloxacin was as 
effective a s  rifampicin and better than erythromycin in preventing death of 
infected guinea pigs (44).
In the present study, the fertile hen's egg was used a s  an in vivo assay  
system for the critical evaluation of clinically useful antibiotics. Antimicrobial 
agents were administered one day post-inoculation and tested  for their ability to 
delay the development of histopathological lesions and the appearance of 
infiltrative cells, reduce organism numbers in tissues and d ecrease  embryo 
mortality. Ciprofloxacin, erythromycin, doxycycline and rifampicin were all 
effective against L. pneumophila infection of the embryonated egg in all aspects 
of testing as  compared with PBS controls. However, results from these 
investigations demonstrated the superior activity of ciprofloxacin in these in vivo
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trials.
The treatment of human legionellosis often com m ences well after the 
disease process is initiated. In this study, the progression of disease was 
monitored at the ultrastructural level and antimicrobial therapy administered to 
eggs to correspond with the appearance of the earliest cellular and sub-cellular 
pathological changes in tissues. It was evident that ciprofloxacin was the most 
effective antibiotic investigated based on its consistent ability to reverse 
ultrastructural lesions induced in response to infection with L. pneumophila.
Although no animal system completely simulates the conditions of 
human therapy, these results established the efficacy of the chick embryo to 
evaluate clinically putative antibiotics for the treatment of human legionellosis 
and to investigate the pathology associated with otherwise fatal experimental L. 
pneumophila infections. The usefulness of ciprofloxacin in the treatment of 
such infections in this animal was also demonstrated in all aspects  of these 
trials. Rifampicin, erythromycin and doxycycline also showed antimicrobial 
activity in this assay  system, but to a  lesser degree. Evidence from this and 
other reports suggested that the use of ciprofloxacin for the treatment of L  
pneumophila experimental infections in animals requires further investigation.
In addition, studies are necessary to determine whether the use of this drug may 
be efficacious in the treatment of clinical legionellosis.
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Table 5.1 LD5 0  values for L. pneumophila in the embryonated 
hen’s egg.
Route of Inoculation cfu/ml
allantoic sac  5.5 x 104
amniotic sac  1.4 x 102
chorioallantoic membrane (CAM) 3.3 x 104
yolk sac  6 .6 x 102
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Table 5.2 Histopathological observations on organs of embryos 
inoculated with 1, 10, 100 or 1000 times the YSLD5 0  of U  
pneum ophila.
Days post-inoculation 
1, 2, 3, 4 5, 6 , 7, 81
Feature
systemic degenerative changes 
in organs
edem a
congestion of blood vessels 
cellular dam age  
inflammatory cell response
+++ = extensive damage, - = not found
1 All features described reflect findings with inoculas of 1, 10 and 100 times the 








Table 5.3 Ultrastructural observations on cells of embryo organs 
inoculated with 100 times the YSLD50 of L. pneumophila.
Cell Damage Days post-inoculation
1, 2 4 ,5
Breakdown of cell and  nuclear membrane
Cytoplasmic clearing
Fatty degeneration




Margination of chromatin and nuclear
clearing
Intercellular spaces  and  cellular vacuoles 
Hemolysis
+++
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
++++ = extensive in all cells examined; +++ = common in many cells; 
+ = rarely found; - = never found
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Table 5.4 Appearance of inflammatory cells in chick embryo 
organs infected with 100 times the YSLD5 0  of L. pneumophila and 
protected with 10 times the MIC of each antibiotic.
Antibiotic MIC (pg/ml) Days post-inoculation






Table 5.5 Ultrastructural cell damage in embryo organs previously 
inoculated with 100 times the YSLD50 of L. pneumophila 












Ciprofloxacin 0.08 28 +++2 +
Rifampicin 0.03 10.5 +++ +++
Erythromycin 0.50 175 + Dead
Doxycycline 0.80 280 + Dead
iDose per egg was based upon 10 times the MIC for each drug and an average 
egg volume of 35 mis.



























Figure 5.1 Schematic illustrating various routes of inoculation and compartments 






Figure 5.2 Schematic illustrating the chorioallantoic route of inoculation of the 
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Figure 5.3 Bacterial viable counts assays  on embryo organs from eggs inoculated 
with the YSLD50of L. pneumophila. Note rapid bacterial growth in all organs 
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Figure 5.4 Bacterial viable count assays on embryo organs from eggs inoculated 
with 10 times the YSLD50 of L. pneumophila. Note increased bacterial growth rate 
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Figure 5.5 Bacterial viable count assays on embryo organs from eg g s  inoculated 
with 100 times the YSLD50 of L. pneumophila. Bacterial growth in organs was 
similar in all organs examined but was less rapid than growth in organs of embryos 
inoculated with 10 times the YSLD50.
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Figure 5.6 Bacterial viable count assay s  on embryo organs from eggs inoculated 
with 1000 times YSLD50 of L. oneumoohila. Note increased bacterial growth in 
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Figure 5.7 Bacterial growth of L. pneumophila in embryo organs previously 
inoculated with 100 times the YSLD50and treated one day post-inoculation with 
1 or 10 times the MIC of antibiotic. Treatment with ten times the MIC of 










C ip r o flo x a c in
R ifa m p ic in




1 2 3 4 6 7 35
Days post-lnoculation
Figure 5.8 Viability rate of embryos previously infected with 100 times 
theVSLDso of L. pneumophila and treated with 10 times the MIC of each 
antibiotic. PBS control (o), ciprofloxacin (■), erythromycin ( ^ )  and rifampicin 
(□)■ Ciprofloxacin was the most efficacious antibiotic used  in these trials.
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Plate 5.1 Histological sections of liver tissue from the chick embryo. 
Hematoxylin and eosin stain.
a) normal tissue with dispersed red blood cells (RBCs) (X 165), b) liver tissue 
five days after inoculation with the VSLD50 of L. pneumophila. Note edematous 
tissue and densely staining inflammatory response within congested  central 
vein (X660).
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Plate 5.2 Histological sections of heart tissue from the chick embryo. 
Hematoxylin and eosin stain.
a) normal tissue (X 165), b) heart tissue five days after inoculation with the 
YSLD50 of L  pneumophila with marked vascular congestion (arrows) (X 165).
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Plate 5.3 Histological sections of spleen from the chick embryo. Hematoxylin 
and eosin stain,
a) normal tissue (X 165), b) spleen 5 days after inoculation with the YSLD50 of 
L. pneumophila. Inflammatory cells are evident within central artery and 
surrounding tissue (X165).
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Plate 5.4 Histological sections of kidney from the chick embryo. Hematoxylin 
and eosin stain.
a) normal tissue showing glomeruli, convoluted tubules and circulating RBCs of 
the kidney (X 165), b) kidney five days after inoculation with the YSLD50 of L 
pneumophila. Note dam aged  sustained by glomeruli (short arrow) as 
compared to the convoluted tubules (long arrow). Inflammatory cells are 
distributed thoughout tissue the tissue (X 660).
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Plate 5.5 Histological section of liver at five days post-inoculation at high 
magnification showing influx of inflammatory cells. Note incidence of PMNLs 
(short arrow) and lymphocytes (long arrow) as  well as  dam aged hepatocytes (X 
1650). Hematoxylin and eosin stain.
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Plate 5.6 Electron micrograph of kidney three days after inoculation with 100 
times the YSLD50 of L. pneumophila. Subtle pathological changes within the 
mitochondria of cells were evident at this time (arrows) alongwith fatty 
degeneration and vacuole formation (X 8,000). Bar=1 pm.
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Plate 5.7 Electron micrograph of heart three days after inoculation with 100 
times the VSLD50 of L. pneumophila. Note extreme d am ag e  to mitochondria 
(arrows) and initial stages of cytoplasmic clearing (X 10,000).
Bar=1 pm.
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Plate 5.8 Electron micrograph of spleen four days after inoculation with 100 
times the YSLD50 of L. pneumophila illustrating ballooning of nuclear 
membranes (short arrow), margination of chromatin material (long arrow), 
vesicle formation within cytoplasmic space (open arrow) and the presence of 




Plate 5.9 Electron micrograph of kidney four days after inoculation with 100 
times the YSLD50 of L. pneumophila. Note the various s tag es  of the hemolytic
process (X 8,000). Bar=1 pm.
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Plate 5.10 Electron micrograph of liver five days after inoculation with 100 times 
the YSLD5o of L. nneumophila illustrating advanced s tages  of the infection. 
Necrotic hepatocytes are bordered by hemolysed RBCS. Cell membranes of 
liver cells are intermittently lysed (X 4,000). Bar=5 pm.
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Plate 5.11 Electron micrograph of heart five days after inoculation with 100 
times the YSLD50 of L. pneumophila showing pathological changes at this 
stage of the infection. Fatty degeneration, intercellular and intracellular 
clearing, margination of chromatin material and membrane lysis are apparent 
(X 4,000). Bar=5 \xm.
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Plate 5.12 Electron micrograph of spleen five days after inoculation with 100 
times the YSLD50 of L. pneumophila. Pyknosis (short arrow) and karyolysis 
(long arrow) of nuclei are evident alongwith the formation of many cytoplasmic 
vesicles (X 6,000). Bar=5 pm.
Plate 5.13 Electron micrograph of spleen tissue four days after inoculation with 
100 times the YSLD50 of L. pneumophila. Cell with intracellular organism 
associated with cellular and sub-cellular pathology (X 8,000). Inset: higher 
magnification of L. oneumoohila organism (X 20,000). Bars=1 pm.
Plate 5.14 Electron micrograph of kidney from embryos treated with 10 times the 
MIC of erythromycin three days after bacterial infection. Thin-sectioned tissue at 
four days post-infection (one day post-therapy) showing improved tissue as  
compared to untreated controls at the same stage of infection. Erythromycin did 
not sustain this level of activity with time (X 10,000).
Bar=l pm.
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Plate 5.15 Electron micrograph of kidney from embryos treated with 10 times the 
MIC of doxycycline three days after bacterial infection. Thin-sectioned material 
at four days post-infection (one day post-therapy) illustrating improved 
presentation of tissue as  compared with untreated controls at the sam e stage of 
infection. Doxycycline was not able to maintain this level of activity with time ■
(X 8,000). Bar=1 urn.
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Plate 5.16 Electron micrograph of kidney from embryos treated with 10 times 
the MIC of rifampicin three days after bacterial infection. Thin-sectioned 
material at four days post-infection (one day post-therapy). Rifampicin treated 
tissue showed some improvement as  compared to untreated tissue at the same
stage of infection (X 4,000). Bar=5 (a.m.
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Plate 5.17 Electron micrograph of kidney from embryos treated with 10 times the 
MIC of rifampicin three days after bacterial infection. Thin-sectioned material at 
eight days post-infection (five days post-therapy). No improvement of the 
condition of the tissue was noted with time (X 4,000). Bar=5 pm.
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Plate 5.18 Electron micrograph of liver from embryos treated with 10 times the 
MIC of ciprofloxacin three days after bacterial infection. Thin-sectioned material 
at four days post-infection (one day post-therapy) exhibiting no significant 
improvement of tissue condition a s  compared to untreated controls at the same
stage of the infection (X 4,000). Bar=5 pm.
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Plate 5.19 Electron micrograph of liver from embryos treated with 10 times the 
MIC of ciprofloxacin three days after bacterial infection. Thin-sectioned material 
at eight days post-infection (five days post-therapy). Note much improved 





Data from these studies indicated that a  molecule or molecules with lectin­
like activity on the surface of this organism may be responsible, at least in part, for 
L. pneumophila binding to host target cells. Further identification and isolation of 
L. pneumophila surface structures which facilitate attachment to target cells may 
lead to the development and production of potentially useful anti-adherence 
vaccines. The process by which L. pneumophila recognized and adhered to host 
cell surfaces represents the earliest, most critical stage of bacterial infection. The 
ability to block these initial events with such prophylactic treatments would 
illustrate a  novel strategy for the prevention of clinical legionellosis.
The chick embryo was established as  a powerful tool for the evaluation of L  
pneumophila virulence and proved a viable alternative to other animal systems for 
the study of the pathology and chemotherapy of the extrapulmonary manifestations 
of experimental L. pneumophila infections. Because of the intracellular nature of 
this organism, in vitro MIC data do not reflect in vivo or clinical results. These 
studies demonstrated the fertile hen's egg as  a readily accessible in vivo system 
for the evaluation of putative antimicrobial therapy for legionellosis and may prove 
of significant value for the evaluation of antibiotic regimens for other facultative 
intracellular pathogens such as Brucella. Yersinia. Listeria. Chlamydia and many 
others. Although, erythromycin (the drug of choice for Legionnaires' disease), 
rifampicin and doxycycline showed antimicrobial activity in this animal system,
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ciprofloxacin, a  newer broad spectrum quinolone antibiotic was the most 
efficacious in these trials.
Studies which characterized the morphological response of L. oneumoohHa 
to clinically relevant antibiotics provided indicators of the bacteriostatic versus 
bactericidal nature of these agents and yielded some information concerning the 
structural nature of the organism. In addition, examination of the microbial damage 
induced by selected antimicrobials was necessary for the interpretation of results 
derived from further in vivo evaluations of these antibiotics.
L. pneumophila is a  human pathogen that cau ses  fatal disease. 
Immunocompromised individuals are particularly susceptible to infection and 
respond variably to the current antibiotic regimens. The present investigation 
partially characterized the adherence of L. pneumophila to host cells and explored 
the possibilities of novel preventative m easures in the form of anti-adherence 
vaccines for human disease. Furthermore, these data delineated the 
pathogenesis and pathology of L. pneumoohila in experimental animal infections 
and illustrated the role of clinically relevant antibiotics in the outcome of disease. 
These results may lead to the development of aggressive combination therapeutic 
regimens in which protective vaccines and new broad-spectrum antimicrobial 
agents  can be used for the prophylaxis and control of clinical legionellosis. Finaily, 
this work clearly demonstrated the superior antimicrobial activity of the quinolones 
and their potential for treatment of human Legionnaires' disease.
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Section VII
7. Possible future studies:
This work has taken a  number of interesting turns and has revealed a variety of 
problems which could usefully be addressed concerning the further characterization of 
the pathogenesis of L. pneumophila:
1) role of humoral and cell-mediated immunity of the chick embryo to L. 
pneumophila infection and the outcome of disease.
2 ) examination of the potential intracellular colonization of the inflammatory 
cells reported here by L. pneumophila.
3) characterization of the role of L. pneumophila toxins in the disease process 
in the chick embryo.
4) role of bacterial toxins and antibiotics in intracellular survival of L. 
pneum ophila.
5) comprehensive characterization of specific L. pneumophila adhesins (outer 
membrane proteins, fimbriae, pili, lectins) involved in adherence to host ceils.
6 ) identification of host cell receptors for L. pneumophila.
7) electron microscopic examination of L. pneumoohila adherence to U937 and 
subsequent internalization processes.
8) effect of selected antibiotics (especially at sub-MIC levels) on L  
pneumophila adherence to host cells.
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9) evaluation of immunosuppressive regimens on the outcome of experimental 
legionellosis in the chick embryo system.
10) determination of the synergistic action of selected antimicrobial agents in 
vitro and in vivo.
11) characterization of the mechanisms of L. pneumophila uptake by host cells
1 7 0
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Media used in biological studies.
1. Cell cultures
1.1 De-ionized water
All water used to make up media was obtained from a Millipore Milli Q 
filtration system. Ten Megohm water was collected, filter sterilized through a  0.2 
pm filter, and one liter aliquots stored at 4° C.
1.2 Phosphate  buffered saline (PBS\
Solutions of PBS were made in de-ionized water a s  follows and
sterilized by autoclaving and stored in 100 ml aliquots in glass bottles at 4° C.
co m ponent grams/liter
NaCI 8.0
KCI 0.2
KH2P 0 4 0.2
Na2H P 0 4 0.15
1.3 Hanks’ Balanced Salt Solution (HBSS)
A concentrated 10 X sterile solution of HBSS with 0.35 g/l sodium 
bicarbonate and phenol red was obtained from Irvine Scientific. For use, the 
stock solution was diluted ten-fold under aseptic conditions with sterile 
de-ionized water. The stock and working strength solutions were stored in 
sterile g lass  bottles at 4° C.
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1.4 Sodium bicarbonate solution (NaHCCh)
A stock 7.5 % solution of sodium bicarbonate was m ade by dissolving 75 
g NaHC0 3  in 1 liter of de-ionized water and sterilized by filtration. Aliquots of
100 mis were placed in sterile bottles and stored at 4° C.
1.5 Bovine calf serum
Sterile bovine calf serum supplemented with iron was obtained from 
Hyclone Laboratories, distributed in 50 ml volumes in sterile plastic tubes and 
stored at -20° C.
1.6 Glutamine
This was obtained in powdered form from Sigma, dissolved in sterile 
de-ionized water to make a  100 X stock (300mM) solution and filter sterilized. 
Aliquots were stored at -20® C.
1.7 Minimal Essential Media with Earles salts and non-essential amino acids 
(MEM)
This medium w as obtained from Irvine Scientific as a  sterile 10 X 
concentrated solution with added phenol red. For use, stock solutions were 
diluted ten-fold with sterile de-ionized water in an aseptic manner. Stock and 
working strength solutions were stored in sterile glass bottles at 4° C.
1.8 Trvosin-EDTA
Trypsin and sodium versenate (EDTA) were obtained in powdered form 
from Sigma and dissolved in 100 ml of warm PBS to make a working solution of
0.05% trypsin and 0.02% EDTA. Aliquots of 10 ml were stored at -20°C.1.8
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Growth medium
MEM with Earles salts was prepared with the following sterile 
constituents:
Com ponent Volume
MEM with Earles salts 450 ml
Bovine calf serum 50 ml
Sodium Bicarbonate (7.5%) 10 ml
Glutamine 5 ml
2 . Organism  growth
2.1 SaiicLmedium
Buffered yeast extract agar supplemented with a-ketoglutarate (BCYEa)
was obtained from Gibco Laboratories (Madison, Wisconsin) and prepared 






a-ketog lu tara te  1.0
agar  15.0
charcoal, activated 2.0
Four ml of a  filter sterilized solution of 10% L-cysteine HCI was then aseptically 
added to 1 liter of medium according to manufacturer's instructions.
1 8 8
2.2 Broth medium
Buffered yeast extract broth supplemented with a-ketoglutarate (BYEa) 
was prepared as  follows:
Component grams/liter
yeast extract 10.0
ACES buffer 1 0 .Q
ferric pyrophosphate 0.25
a-ketoglu tara te  1.0
Constituents were added to one liter of distilled water, allowed to 
dissolve, filter sterilized through a 0.2pm filter and collected aseptically. Four mi
of a  filter sterilized 10% solution of L-cysteine HCL was aseptically added to the 
medium prior to use.
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A ppend ix  2
1. Reagents and materials used in histological studies.
1.1 Harris' Alum Hematoxylin
This solution was comprised of the following:
Component Amount
hematoxylin crystals 5.0 g
absolute alcohol 50 ml
aluminum ammonium sulfate 100 g
de-ionized water 1000 ml
mercuric oxide 2.5 g
Hematoxylin crystals were dissolved in alcohol and the aluminum ammonium 
sulfate dissolved in water. The two solutions were then mixed and rapidly 
brought to a  boil. Mercuric oxide was added slowly and the mixture reheated 
for 15-20 min. This was kept covered in a glass coplin jar ready for use.
1.2 Stock 1% aqueous eosin solution
The following components comprised this solution:
Component Amount
water soluble eosin 10 g
de-ionized water 1000 ml
glacial acetic acid 2.0 ml
This were mixed and the solute allowed to dissolve. The stock solution was 
kept in a  glass stoppered bottle and stored at 20° C. A working solution was 
made by mixing 50 ml of the stock solution with 120 ml absolute alcohol, 30 mi 
de-ionized water and 1.0 ml glacial acetic acid.
1.3 Acid alcohol solution
This was made by adding 70% (710 ml of 95%alcohol with 290 ml
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deionized water) to 10 ml concentrated hydrochloric acid, and stored in a 
stoppered bottle at 20° C.
1.4 Saturated lithium carbonate
This was made by dissolving 4.5 g of lithium carbonate in 450 mi de­
ionized water and stored in a  stoppered bottle at 20°C.
1.5 Buffered formalin solution
A 10% solution of formaldehyde (VWR) was prepared in PBS and stored 
in a stoppered glass bottle at room temperature.
1.6 Preparation of histological sections
Tissue samples were harvest from embryos and fixed in 10% buffered 
formalin. Samples were then embedded In paraffin with a  Lab Tek Tissue 
Processor and trimmed with a razor blade. Four micron sections were cut with a 
American Optical rotary microtome, attached to glass slides and prepared for 
staining.
1.6.1 Hematoxylin and eosin staining procedure 
The following staining procedure was used:
Treatment Time
Histoclear (two changes} 2 min
100% alcohol (two changes) 1 min
95% alcohol (two changes) 1 min
de-ionized water 3 dips
Harris' Hematoxylin 6 min
Running tap water 2 min
Acid alcohol 6-8 dips
de-ionized water 3 dips
lithium carbonate 7 dips
running tap water 15 min
eosin 1 -4 min
95% alcohol (two changes) 15 sec
100% alcohol (two changes) 15 sec
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Appendix 3
Reagents and materials used in electron microscopy studies.
1. Negative staining
1.1 Grids
Copper 400 mesh grids were supplied by Electron Microscopy Sciences 
(EMS) and were used in all studies.
1.2 Formvar
This was obtained from EMS as a dry powder. A stock 2% solution was 
made by dissolving one gram of formvar in 50 ml electron microscopy grade 
ethylene dichloride (EMS). Remaining solid after vigorous shaking dissolved 
upon standing overnight. Stock solution was stored in glass stoppered bottles 
in a  desiccator until use.
Working solution was made up freshly as a 0.2% solution by mixing 18 
ml ethylene dichloride with 2 ml stock formvar solution.
1.3 Formvar coating of grids
A clean dry glass slide was dipped into 20 ml 0.2% working strength 
formvar solution in a Coplin jar, removed and drained. When dry, the film was 
cut in situ into suitable sized squares using a  sharp scalpel, and these  squares 
were floated off onto the surface of de-ionized water by carefully submerging at 
a  shallow angle the formvar coated slide. In reflected light, the formvar films 
could be seen  as  pale opalescent squares floating on the surface of the 
de-ionized water. Copper grids were placed (matt side down) on top of the films 
and collected from the water by carefully placing pieces of Whatman No. 1 filter 
paper over the films. Filter papers with adherent formvar films and grids were
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collected and dried.
1.4 Phosphotunastic acid fPTA) negative stain
A 1% (w/v) solution was made by dissolving potassium 
phosphotungstate in 100 ml de-ionized water and the pH was adjusted to 6.7 
using fresh aqueous potassium hydroxide. Any turbidity remaining after 
standing at room temperature for 24 hours was removed by centrifugation at 
10,000 RPM in a  Beckman Microfuge 12. The stain was stored at room 
temperature and used as  required.
1.5 Negative staining procedure
Equal volumes of a  bacterial suspension of approximately 5 x106 cfu/ml 
were mixed with 1% PTA on a  glass slide and a  drop of the resultant mixture 
w as  placed onto a formvar coated grid. The mixture was allowed to remain on 
the grid for about 10-15 seconds before being drained off by touching the edge 
of the grid with a  piece of Whatman No. 1 filter paper. The rate at which the 
bacteria-stain mixture drained from the grid into the filter paper was indicative of 
the  suitability of the preparation. Drops that drained quickly usually contained 
insufficient material.
2 . Embedcing and thin-sectioning
2.1 Grids
EMS 400 mesh copper grids were used in all studies.
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2 .2  Cacodvlate buffer
This was made by adding the appropriate amount of sodium cacodylate 
(EMS) to one liter of de-ionized water to give the following concentrations: 
Sam ples  Concentration
bacteria 0.05 M (supplemented with 10mM M gS04)
tissue 0.10 M
These solutions were adjusted to a pH of 7.2 using hydrochloric acid and stored
at 4 o C until required.
2.3 G.lutaraldehvde
Glutaraldehyde was obtained from EMS as an electron microscopy 
grade 25% (v/v) aqueous solution. The stock solution w as stored in at 4° C and 
working 3% (v/v) solutions were made freshly in cacodylate buffer a s  required.
2.4 Osmium tetroxide
A stock 2% (w/v) solution of OSO4 (Stevens Metallurgic Corporation) was 
made by dissolving the contents of a  ig  ampule in 50 ml cacodylate buffer. 
OSO4 emits a dangerous vapor and was always handled in a  fume hood. The 
solute was completely dissolved after standing overnight at 4° C. The stock 
solution was stored at 4° C in a tightly capped bottle covered with aluminum foil. 
The working 1% solution was made by mixing equal volumes of the stock 2% 
solution and cacodylate buffer.
2.5 Ethanol series
A graded ethanol series was made by mixing appropriate amounts of dry 
absolute ethanol and cacodylate buffer. The 50% and 70%  solutions were 
stored at 4 o C and the 90%. 95% and absolute ethanol solutions were stored at
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room temperature. (Percentages refer to the concentration of ethanol).
2.6 Propylene oxide
This w as obtained from EMS and was supplied ready for use. The 
container was kept tightly stoppered at all times.
2.7 Resin mixture
The resin used in all studies is described in 2.7.1 below. All volumes 
were m easured in disposable 50 ml tri pour beakers from VWR except for 
dibutyl phthalate and DMP-30 which were m easured using one ml disposable 
syringes without needles.
2.7.1 Epon-araldite resin mixtur£
The resin mixture was comprised of the following:
Com ponent Proportion
1) Epon 812 (resin) 5 parts
2) Dodecenyl succinic anhydride (DDSA) 11 parts
3) Araldite (resin) 3 parts
4) Dibutyl phthalate (plasticizer) 0.8 parts
5) Methyl nadic anhydride (DMP 30) (accelerator) 0.4 parts
Components were added to a glass bottle in this order and vigorously shaken 
for 10 min with the exception of DMP 30 which was added just before resin was 
required for use. Complete resin (with DMP-30) was then vigorously shaken for 
an  additional three to five min. This resin mixture was polymerized at 60° C for 
24 h.
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2.8 Embedding and thin-sectioning procedure
For bacterial samples, organisms were harvested, fixed in 3% buffered 
glutaraldehyde, washed three times in 0.05 M cacodylate buffer containing 
lOrnM MgSC>4 and pre-embedded in 3% (w/v) Noble agar. Cubes of 1 m m 3  
:hickness were cut and post-fixed in 1% OSO4 in cacodylate buffer for 1 h.
Tissue samples were harvested, rinsed in 0.1 M cacodylate buffer and 
fixed in 3% buffered glutaraldehyde. One mm3 cubes were cut and post-fixed in 
1% OSO4 in cacodylate buffer for 1 h, All samples were rinsed in cacodylate 
buffer three times followed by a dehydration procedure of immersion for five 
min in each of 50%, 70%, 90% and 95% ethanoi in cacodylate buffer. 
Dehydration of samples was completed by two rinses of ten min each  in 
absolute alcohol. Ethanol was removed by pipette and the specimens rinsed 
twice in propylene oxide. Specimens were not allowed to dry during any step of 
this procedure.
Resin infiltration was done by placing the samples in a  2:1 mixture of 
propylene oxide and complete resin for one hour, and this mixture w as then 
replaced by a 1 :2 mixture of propylene oxide and complete resin for an 
additional hour. Specimens were placed in complete resin for one hour after 
which the resin was changed for fresh complete resin which had been 
degassed  for 20 min in a  vacuum desiccator. These remained in the degassed  
resin for one hour, removed and located in embedding molds. The molds were 
filled with d egassed  complete resin. Specimens were manipulated using 
wooden swab sticks sharpened at one end to form a flexible spatula which was 
pre-treated by dipping in degassed  complete resin. These treated spatulas
1 9 6
were placed at 60° C for one hour prior to use to allow the resin end to dry and 
so as  to prevent the introduction of air bubbles around the specimen. Blocks 
were labelled with hardened paper and polymerized in a 60° C oven for 24 h. 
After removal from the oven, blocks were left at room temperature for two or 
three days to allow complete hardening of the resin prior to their removal from 
the molds. Embedding of samples was completed in one day and was followed 
by a 24 h polymerization, the whole procedure taking approximately 30 h to 
complete. The embedding schedule and times required are summarized in 
Table 1.
Polymerized blocks were placed in the round chuck of a LKB Ultratome III 
ultramicrotome and trimmed mechanically with a glass knife made with an LKB 
knife maker.
When blocks had been appropriately trimmed, ultra thin sections were 
cut using the thermal advance on the ultramicrotome and using a Diatom 
diamond knife filled with clean de-ionized water. The diamond knife edge v. as 
cleaned with a  soft clean pith stick. Sections giving grey or silver interference 
colors (60-90 nm thickness) were chosen. Individual sections and small 
ribbons were picked up on copper grids. Grids were submerged in the boat and 
sections located above them with a  mounted eyelash. Sections were removed 
by lifting the grid out of the water and the grids blotted dry by touching the edge 
to a  piece of filter paper.
Ultrathin sections were stained with 5% aqueous uranyl acetate for 60 
seconds by floating grids, sections downward, on a drop of stain placed on 
parafilm and covered by a  glass petri dish lid. Grids were removed and
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sections washed thoroughly in a running stream  of de-ionized water using 
approximately 15 ml per grid, after which they were blotted and allowed to dry. 
The grids were then held in fine forceps and a  drop of lead citrate placed on 
them for 20 seconds, after which they were washed as before using 
approximately 25 to 30 ml de-ionized water per grid. Grids were blotted and 
allowed to dry a s  before, Stain was removed from the stock bottles using a  fine 
pasteur pipette with the tip located about 5mm below the meniscus. The first 
drop in the pipette was always discarded, thus ensuring minimal stain deposit.
Thin-sectioning was performed under strictly dust free conditions and all 
materials coming into contact with sections, knife or boat water were stringently 
cleaned and rinsed under running de-ionized water. Sections were examined 
and photographed in a  Hitachi H600 electron microscope at 75 kV, using 
various instrumental manipulations.
2.9 Stains for ultra thin sections
2.9.1 Urany! acetate
A 5% (w/v) solution of uranyl acetate w as made by dissolving 1 g in 20 ml 
de-ionized water. The solid was found to dissolve completely upon standing 
overnight at room temperature. The solution w as filtered through a  Whatman 
No. 2 filter paper and stored in a  dark glass-stoppered bottle at room 
temperature.
2.9.2 Lead citrate
One pellet sodium hydroxide was dissoved in 15 ml boiled cooled d e ­
ionized water. This solution was added to 0.1 g lead citrate in a  glass screw- 
capped bottle and dissolved by shaking. A further 10 ml boiled cooled de-
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ionized water was added, and the stain was stored tightly capped at room 
temperature.
3 . Scanning electron microscopy (SEM)
3.1 Hexamethvldisilaxane (HMDS1
This was obtained from Polysciences, Inc. (Warrington, Pa.) and kept 
tightly capped in a fume hood prior to use.
3.2 SEM procedure
Bacterial specimens were fixed in 3% glutaraldehyde in cacodylate 
buffer, washed three times in buffer and dehydrated in 50%, 70%, 90%, and 
absolute ethanol. Samples were then treated with two changes of HMDS and 
applied to specimen stubs with double sided sticky tape. Stubs were coated 
with 20 nm gold/palladium at a  target to specimen distance of 5 cm with a 
current of 15 mA for 4 min. Specimens were viewed in a  Hitachi H600 electron 
microscope in the scanning mode at an accelerating voltage of 40 kV.
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Table 1 . Embedding of specimens for electron microscopy. 
P ro ce d u re  T im e
1) Wash in cacodylate buffer 15 min
2) Fix in 3% glutaraldehyde in cacodylate buffer 30 min
3) Wash in cacodylate buffer (ten changes) 30*40 min
4) Post*fix in 1% OsC>4 1 h
5) Wash in cacodylate buffer 5 min
6) Dehydrate in ethanol series in cacodylate buffer 20 min
7) Complete dehydration in absolute ethanol 40 min
and propylene oxide
8 ) Resin / propylene oxide mixtures 120 min
9) Resin (two changes) 120 min
10) Polymerization 24 h
Total Time Required Approximately 30 h
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Appendix 4
1. Production of polyclonal antisera against L. pneumophila.
1.1 Babbits
White New Zealand rabbits were obtained locally and pre-bled to a ssess  
pre-immunization level of antibodies against L. pneumophila.
1.2 Antigen preparation
Whole cells of L, pneumophila (approximately 1 x 1 09 cfu/ml) were 
formalin fixed in 1% (v/v) formaldehyde (VWR) in PBS and a small volume of 
sterile egg yolk. Prior to immunization of rabbits, 1 ml of this solution was mixed 
with an equal volume of Freund's Incomplete adjuvant (VWR) and 
homogenized in a Sorval Omni Mixer.
1.3 Bleeding procedure
1.3.1 Ear bleed
Samples of blood obtained for antibody titer analysis following 
immunization were drawn aseptically from the central artery of one of the 
rabbit's ears. Vasodilation of this artery was achieved by warming the rabbit's 
e a r  with a 15 watt bulb of a  portable lamp. When the artery w as suitably 
dilated, the e a r  was sw abbed with alcohol and a 21 gauge needle was inserted 
to release approximately 5 ml blood into a sterile test tube. The ear was then 
swabbed again with alcohol and treated appropriately to stop the bleeding.
1.3.2 Cardiac puncture
Once the antibody titer had reached a suitable level following 
immunization, the final volume of blood was collected by cardiac puncture and 
exsanguination of the rabbit. The rabbit was anesthetized with the addition of a
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sodium solution of Nembutal into the peripheral vein of the ear and blood 
drawn through an 18 gauge needle and syringe inserted through the chest 
cavity into the heart. The rabbit was exsanguinated in a humane fashion with a 
final injection of Nembutal into the heart.
Blood obtained from ear bleeds and cardiac puncture was allowed to clot 
overnight at 4o C and the resultant serum decanted for titer analysis or stored 
frozen in 1 ml aliquots at -70° C.
1.4 Antibody titer assay
An indirect immunofluorescence assay (Materials and Methods, Chapter 
Four) was used to measure the titer of sera  drawn from rabbits. Once obtained, 
doubling dilutions of the serum were made in PBS and used immediately in the 
analysis. Formalin fixed whole L pneumophila cells were added to multiple 
spots on glass slides and allowed to dry. Dilutions of the serum were added to 
these a reas  as the primary antibody in an indirect immunofluorescence assay  
and allowed to incubate at 37° C for 1 hour. Three-fold w ashes  were m ade with 
PBS whereupon goat anti-rabbit FITC conjugated serum was added to all spots 
on the glass slide and incubated for 1 hour at 37° C. These were washed three 
times and viewed with an BH-2 Olympus microscope in the 
immunofluorescence mode. Appropriate scores of immunofluorescence for 
each dilution were made and the most diluted spot which gave a  positive score 
selected as  the titer.
1.5 Immunization procedure
Rabbits were pre-bled and analyzed for pre-immunization antibody 
against L. pneumophila. A small area of the rabbits back was clean shaven,
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swabbed with alcohol and the antigen-adjuvant mixture administered into 10 
sub-cutaneous sites with a  21 gauge needle and syringe. These sites were 
swabbed with alcohol again and examined for unusual reactions. The rabbits 
were boosted with a similar antigen mass 2 and 4 weeks later. Antibody titer 
was checked every week during this time.
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